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U¨ber die Geduld
Man muss den Dingen
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Reifen wie der Baum,
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die da sind, als ob die Ewigkeit
vor ihnen la¨ge,
so sorglos, still und weit...
Man muss Geduld haben
Mit dem Ungelo¨sten im Herzen,
und versuchen, die Fragen selber lieb zu haben,
wie verschlossene Stuben,
und wie Bu¨cher, die in einer sehr fremden Sprache
geschrieben sind.
Es handelt sich darum, alles zu leben.
Wenn man die Fragen lebt, lebt man vielleicht allma¨hlich,
ohne es zu merken,
eines fremden Tages
in die Antworten hinein.
Rainer Maria Rilke
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ABSTRACT
The innate immune system evolved a plethora of germline encoded pattern recognition
receptors that are able to sense viral nucleic acids in order to restrict infection. Ex-
ceptional progress has been made in the understanding of viral nucleic acid sensing.
However, surprisingly little is known about the ability of cells to degrade viral nucleic
acids. RNA turnover is a highly conserved process and tightly controlled to only target
erroneous RNAs for degradation. Intact cellular messenger RNAs are protected from
5’-degradation by a 5’-cap structure. Before being a substrate for 5’-exonucleases, the
5’-cap structure has to be removed by the decapping protein 2 (DCP2 or NUDT20).
This decapping leaves a monophosphorylated RNA that can serve as a substrate for the
exonuclease 1 (XRN1). Nucleic acids of some RNA viruses bear a triphosphorylated
5’-end. This chemical structure is a feature exclusively foreign nucleic acids introduce
into cells and does not serve as a substrate for XRN1.
In this dissertation, I discovered a novel mechanism that prepares viral 5’-triphosphorylated
RNAs for degradation. Employing a siRNA screen, recombinant proteins as well as in
vitro and in vivo experiments, I identiﬁed the protein Nudix hydrolase 2 (NUDT2) as
central protein to prepare 5’-PPP-RNA for degradation by XRN1. I could show that
the activity of NUDT2 is unspeciﬁc in terms of the 5’-triphosphorylated RNA substrate
and can dephosphorylate substrates of a broad range without showing any sequence or
structural requirements. NUDT2 releases two phosphate groups in a sequential manner,
leaving a monophosphorylated RNA that can serve as a substrate for XRN1. Thereby,
NUDT2 initiates a RNA decay mechanism that is speciﬁc for viral 5’-PPP RNA. Its
importance is highlighted by the increased replication of PPP-RNA generating Vesicular
stomatitis virus infected cells lacking the Nudt2 gene.
Besides identifying this novel pathway to process and remove 5’-PPP-RNA, I also
contributed to gain a better understanding on how the viral restriction factor interferon-
induced protein with tetratricopeptide repeats 1 (IFIT1) discriminates host from viral
nucleic acids. Infection of IFIT1 mutant cells emphasized the importance of IFIT1
mediated virus restriction and expanded our knowledge on important RNA binding
sites.
xi
Abstract
Taken together, this work describes the functional characterization of a viral RNA speciﬁc
degradation route involving the phosphatase NUDT2 and gives further insights into the
discrimination of self and non-self nucleic acids by the viral restriction factor IFIT1.
Both projects deepen and enhance our understanding of the execution mechanisms of
innate nucleic acid immunity.
xii
PREFACE
This thesis is written in a cumulative style. The ﬁrst part of chapter one introduces
general knowledge of RNA biology, particular focusing on RNA degradation pathways.
The second part of chapter one describes nucleic acid immunity including pattern
recognition receptors, the discrimination of self and non-self RNA, antiviral restriction
factors, and an introduction to the role of nucleases and immunopathologies triggered
by the deregulation of nucleic acid immunity. Section I.2.4 of the introduction was
published in the Journal of Interferon & Cytokine Research:
Anna Gebhardt, Beatrice T. Laudenbach, Andreas Pichlmair, Discrimination of Self and
Non-Self Ribonucleic Acids. J Interferon Cytokine Res 37, 184-197 (2017).
The third and fourth part of the introduction describes viral RNA degradation pathways
and a general introduction to the background of mammalian phosphatases.
The second chapter includes my results in form of manuscripts already published or
prepared for submission:
Beatrice T. Laudenbach, Alexander Reim, Markus Moser, Arno Meiler, Janos Ludwig and
Andreas Pichlmair. NUDT2 initiates viral RNA degradation by removal of 5’-phosphates.
Submitted to Science (2018)
Yazan M. Abbas, Beatrice T. Laudenbach, Sau´l Mart´ınez-Montero, Regina Cencic, Matthias
Habjan, Andreas Pichlmair, Masad J. Damha, Jerry Pelletier, and Bhushan Nagar. Structure of
human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing
N1 and N2 ribose 2’-O methylations. Proc Natl Acad Sci U S A 114, E2106-E2115 (2017).
The last chapter features the discussion and outlook.
All publications are reprinted with permission and copyright of the publications belongs
to the publishers.
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1. RNA Biology
1.1 Ribonucleic Acids
The amount of ribonucleic acid (RNA) that is produced by a eukaryotic cell is striking.
Over 2000 ribosomal RNA molecules are synthesized per minute along with messenger
RNAs (mRNAs) coding for thousands of genes, transfer RNAs (tRNAs), small nuclear
RNAs (snRNAs) and small nucleolar RNAs (snoRNAs). The metabolic expenses are
huge. The synthesis of all RNA species involves several processing reactions, transitions
between subcellular compartments and cycling between diﬀerent protein complexes.
The diﬀerent types of RNA are generated in the nucleus by three cellular RNA poly-
merases (RNA Pol-I, RNA Pol-II, and RNA Pol-III). All three polymerases give rise to
a precursor transcript bearing a 5’-triphosphate (5’-PPP) group. Before being exported
to the cytoplasm the RNA precursors get variably processed.
Ribosomal RNAs (rRNAs) constitute the largest portion accounting for about 80%
of total RNA. Transcription by RNA Pol-I gives rise to a 45S primary transcript
(pre-rRNA) carrying a 5’-PPP-RNA structure. A considerable amount of chemical
modiﬁcations are made to the precursor rRNA including hundreds of isomerizations
of uridines to pseudouridines and methylations of the 2’OH position of the nucleotide
sugars1. Endonucleolytic cleavage and removal of the external and internal transcribed
spacer regions (ETS and ITS) leads to the maturation of the precursor into the 28S,
18S, and 5.8S rRNAs2. The processed ribosomal RNAs then carry a 5’-monophosphate
structure (Figure 1).
RNA Pol-III transcribes an additional set of three diﬀerent classes comprising the 5S
rRNA (Class I), tRNAs (Class II) - the second largest proportion of RNAs accounting
for 15% of total RNA in a cell - as well as many small noncoding genes (Class III)3;4.
The latter include 7SK RNA, 7SL RNA, U6 snRNA, vault genes (HVG), hY RNA, H1
RNA, MRP RNA and others5. tRNAs undergo by far the most extensive processing in
order to provide correct function and structure. First, Ribonuclease P and Ribonuclease
Z cut the 5’-leader and 3’-trailer sequence, respectively, leaving a 5’-monophosphorylated
tRNA precursor. Second, tRNA nucleotidyltransferase - a specialized RNA polymerase -
adds the essential three 3’-terminal nucleotides CCA to the tRNA (Figure 1)6. Moreover,
some tRNA precursors contain introns that have to be spliced out. In addition, over 17%
of all nucleotides in precursor tRNAs are chemically modiﬁed. More than 50 diﬀerent
types of tRNA modiﬁcations are known including methylations, isomerization from
uridines to pseudouridines and the widespread deaminations of adenines to inosines and
cytidines to uridines7.
Transcription of RNA Pol-II gives rise to mRNAs and many nonprotein-coding non-
coding(nc)RNAs, such as micro RNAs (miRNAs), snRNAs and snoRNAs. In case of
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Figure 1: Processing and maturation of cellular RNA transcripts originating from the
three RNA polymerases RNA polymerase I, RNA polymerase II and RNA polymerase III.
mRNAs, the nascent RNA molecule is processed by coupling a guanine monophosphate
nucleoside to the RNA precursor forming the 5’-cap structure (Cap)8. The 5’-cap is
further processed by methylating the N7-position of the guanosine directly after capping,
thereby generating the N7-methylguanylate cap (Cap-0). In addition, the 2’-O-position
of the ﬁrst (Cap-1) and second ribose (Cap-2) can be methylated9.
After capping, a poly(A) tail is added to the 3’-end of the mRNA chain to protect the
molecule from rapid decay in the cytoplasm, to facilitate export from the nucleus and
to aid transcription termination10;11. The poly(A) tail interacts with poly(A) binding
proteins (PABP) in order to protect the structure from exonucleases.
In the ﬁnal step of mRNA processing, introns are removed and exons are again conjugated
(Figure 1). This splicing reaction is carried out by a large protein complex called the
spliceosome. The 5’-end of snRNAs is processed as well by unique 5’-cap structures
including 5’-trimethylguanosine caps (Sm-class snRNAs) or 5’-monomethylphosphate
caps (LSM-class snRNAs transcribed by RNA Pol III)12. Spliceosomal snRNAs are as
well extensively 2’-O- methylated and pseudouridylated at conserved residues important
for proper function similar to rRNAs13.
Only recently, through development of high-throughput sequencing techniques, it was
found that internal nucleotides of mRNAs can be chemically modiﬁed to pseudouridines
as well14;15. Observations indicate that pseudouridylation of mRNAs may play an
6
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important biological role since cellular stress, such as starvation, immune stimulation or
heat shock can lead to pseudouridylation of completely novel sites14;16.
The pervasiveness of all RNA modiﬁcations is important for proper structure and function
of RNAs and, importantly also allows quality-control mechanisms to distinguish mature
RNA from their precursors.
1.2 RNA Degradation
The synthesis of proteins is one of the most costly biochemical processes. It requires a
remarkable amount of energy and has to dynamically adapt to environmental changes
the cell encounters in order to exclusively produce proteins that are needed at a given
time. This regulation is partially achieved by degradation of mRNA, eventually leading
to changing patterns of protein synthesis. By decay of RNA molecules, ribonucleotides
can be recycled and incorporated into newly synthesized RNAs.
Besides controlling protein synthesis, RNA degradation machineries need to prevent the
accumulation of nonfunctional RNAs with defects in folding, defective RNA modiﬁcations
or incorrectly assembled proteins. RNA degradation is a fundamental cellular process
that has to be tightly controlled to accurately spot RNAs to target them for destruction.
RNA decay processes can be subdivided into RNA quality control, mRNA turnover
and the processing of RNAs. In RNA quality control all classes of RNA are monitored.
Surveillance pathways constantly detect aberrant RNAs that can originate from various
events, including mutations in the gene leading to premature termination of translation,
error-prone transcription or pre-RNA processing. Quality control pathways are also able
to detect non-functional RNAs which are generated by the transcription of intergenic
regions17 or parasitic RNAs originating from transposons. Turnover of mRNAs is
another cause for RNA degradation and regulates protein synthesis and abundance.
Related to mRNA turnover, ncRNAs are constitutively degraded and thereby form
a contrast to the very stable group of rRNAs. Processing of RNAs in the nucleus
represents the third cause for RNA degradation since all types of RNA are synthetized
in the nucleus as larger precursors by the three RNA polymerases before they undergo
trimming of the 5’- or 3’-ends. This trimming events, but also the generation of excised
fragments or introns, necessitates their removal and governs large parts of the nuclear
RNA degradation machinery.
RNA polymerase I, II, and III are able to generate very diﬀerent types of RNA molecules
however cellular RNA decay pathways seem to not distinguish between their products
but rather constitute a universal arsenal surveilling all cellular RNAs.
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1.2.1 Degradation of RNA Polymerase II transcripts
RNA Polymerase II transcription leads to the generation of diﬀerent classes of RNA
including mRNA, snRNAs, snoRNAs and miRNAs. In eukaryotic cells, two main mRNA
degradation pathways are responsible for the turnover of bulk mRNAs: 5’ to 3’ decay
employing the exonuclease 1 (XRN1) and 3’ to 5’ degradation through the exosome
complex. Both pathways are commenced by the removal of the poly(A) tail in a process
called deadenylation. As a second step, either the 5’-cap is removed by decapping
enzymes and cellular nucleases proceed with 5’-3’ degradation of the RNA body or
alternatively, the second major mRNA decay route proceeds in 3’-5’ direction through
engaging the exosome complex18.
In addition to the two main mRNA degradation pathways there are more specialized
mechanisms in place to detect and degrade non-functional RNAs. RNAs containing
premature stop codons are recognized and degraded in a process called nonsense-
mediated decay (NMD), whereas turnover of RNAs lacking translation termination
codons occurs via nonstop decay (NSD)
1.2.1.1 RNA Deadenylation
The initial and rate-limiting step for bulk mRNA decay is deadenylation. The main
cytoplasmic deadenylase complexes are the C-C-chemokinrezeptor type 4 - negative
regulator of transcription (CCR4-NOT), poly(A)-nuclease 2 and 3 (PAN2-PAN3) and
poly(A) ribonuclease (PARN) complexes. Each of these complexes has unique properties.
In eukaryotes, the predominant deadenylase activity comes from the CCR4-NOT complex
including ﬁve conserved subunits: CCR4, NOT1, NOT2, NOT3/5, and CAF1/ POP219.
Two of the subunits, namely CCR4 and CAF1/POP2, are responsible for the catalytic
3’-5’ poly(A) exoribonuclease activity of the complex (Figure 2). CCR4 - originally
identiﬁed in yeast - has several homologs in mammals that form a similar complex
containing CNOT6 (Ccr4a), CNOT6L (Ccr4b). Similarly, CAF1/POP2 constituting
the second catalytic subunit of the CCR4-NOT complex, is widely conserved and has
three mammalian homologues: CNOT7 (hCaf1), CNOT8 (hPop2) and CAF1Z20. The
activity of CCR4-NOT is inhibited PABP21.
The second enzyme complex exerting cytoplasmic mRNA deadenylation activity is the
PAN2-PAN3 complex. Interestingly, in comparison to the CCR4-NOT complex the
PAN2-PAN3 complex is dependent on PABP. PAN2 executes the catalytic function of
the complex (Figure 2). Although the PAN2-PAN3 complex does not degrade the entire
poly(A) tail, it is responsible for an initial shortening of the poly(A) tail to a length of
8
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80 nucleotides22. Deadenylation is then continued by the CCR4-NOT complex.
PARN is the ﬁnal enzyme known to deadenylate mRNAs and is unique in that its
activity is increased by the existence of a 5’-cap structure23 but inhibited by cap-binding
proteins (Figure 2)24. The catalytic subunits CCR4, CAF1, PAN2 and PARN belong
to the RNAse D-type family having Mg2+-dependent 3’-5’ exoribonuclease domains.
Interestingly, biochemical studies indicate that the diﬀerent deadenylase complexes
prefer speciﬁc mRNA substrates. The CCR4-NOT complex and PARN select mRNAs
without PABP bound to the poly(A) tail for deadenylation, whereas the activity of
the PAN2-PAN3 complex depends on PABP binding. This selection of messenger
ribonucleoprotein (mRNP) substrates shows that deadenylation and therefore mRNA
turnover can be controlled by the architecture of mRNPs and the associated proteins.
1.2.1.2 The exosome complex
Following deadenylation of mRNAs, one possible degradation route is 3’-5’ decay by
the exosome complex. The RNA exosome is a large multiprotein complex forming a
barrel-like structure. In eukaryotes, the core part with its nine subunits (barrel: RRP41,
RRP42, RRP43, RRP45, RRP46, MTR3 and cap: CSL4, RRP4, RRP40) is highly
conserved (Figure 3A). It is very similar to the structure and domain organization of
9
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the bacterial proteins polynucleotide phosphorylase (PNPase) and RNase PH. RNase
PH is a bacterial tRNA processing enzyme forming a hexameric ring of six RNase PH
proteins25, whereas PNPase is a RNA degrading protein using phosphate as attacking
group. PNPase forms a trimeric complex of one KH and S1 RNA binding domain and
two RNase PH domains26, a structure very similar to the one of the exosome. The
trimeric ring of the exosome is composed of proteins containing S1 and KH domains and
the hexameric ring of RNAse PH-like proteins. However in contrast to these bacterial
RNA degrading complexes, the internal chamber of the exosome is catalytically inactive.
Only an additional subunit (RRP44 or DIS3) confers catalytic activity to the complex27.
Therefore, single-stranded RNA molecules that enter the exosome through a pore in the
S1 and KH-domain containing cap are then channeled through the barrel to the catalytic
DIS3 subunit (Figure 3A). Although catalytically inactive, the barrel itself is important
as it serves as a scaﬀold for the binding of regulatory proteins and to guide and restrain
the substrate to the catalytic active site28. The chemical reaction performed by DIS3
constitutes a hydrolysis reaction. This is in contrast to the bacterial phosphorylytic
reactions of PNPase and RNase PH. However, the hydrolase activity has the advantage
that the RNA substrate is irreversibly cleaved, while phosphorylytic reactions can be
reversed29. During the hydrolysis reaction, single nucleotides are cleaved oﬀ from the
polynucleotide chain and no intermediates are released until the mRNA chain is trimmed
to a four-nucleotide remnant, which is eventually released. The scavenger decapping
enzyme (DcpS) is then able to decap this short oligonucleotides and release an m7GMP
cap structure30.
In addition to its exoribonuclease activity (RNase II-like domain) DIS3 also provides
endonuclease activity. In the nucleus the exosome also associates with an additional
subunit (RRP6) constituting the eleventh subunit and contributing for another exori-
bonuclease activity31. RRP6 plays an important role in trimming rRNAs, snRNAs and
snoRNAs during RNA processing in the nucleus32.
In order to degrade RNA, the exosome has to associate with regulatory protein complexes:
the nuclear TRAMP complex33 and the cytoplasmic SKI complex (Figure 3B)34, both
of which have ATP-dependent helicase activity. The nuclear TRAMP complex adds
short poly(A) tails to the 3’-end of its substrates. This adenosine-tag is supposed to
provide a single-stranded interaction site for the exosome complex in the nucleus (Figure
3B)17. In the cytoplasm, the Ski complex is suggested to directly link RNA unwinding
by its helicase activity to RNA degradation by the exoribonuclease activity of DIS3
through one uninterrupted channel35.
10
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Figure 3: The eukaryotic exosome complex. A: Domain structure and organization of
the exosome complex. B: Degradation of nuclear and cytoplasmic RNA species by the exosome
complex
1.2.1.3 Canonical 5’ to 3’ mRNA decay
As an alternative to being directly degraded by the exosome, deadenylated RNA can be
subject to the second main route of RNA degradation, where deadenylation is followed
by decapping.
The protein with main decapping activity in humans is mRNA-decapping enzyme 2
(DCP2)36. However in vivo, the decapping activity of DCP2 alone is not suﬃcient and
additional activators, the so called enhancers of decapping (EDCs), are required for
full activity. In humans, DCP1 interacting with DCP2 strongly stimulates decapping
activity. Additionally, the heptameric Sm-like protein 1-7 (LSM1-7) complex binds the
3’-end of deadenylated RNAs, thereby promoting decapping (Figure 4). Other LSM
proteins like enhancer of decapping-3 (EDC3 or LSM16), RNA-associated protein of
55kDa (RAP55 or LSM14) are also involved in decapping37. The proteins DExD/H-box
RNA helicase DHH1 and PAT1 are able to directly mediate translational repression
through which decapping is stimulated since decapping and translation are two distinct
processes directly competing with each other.
EDCs interact with each other, with DCP2 directly as well as with the ribonuclease
XRN1, providing a direct connection between 5’-3’ RNA degradation and decapping38.
In general DCP1 and DCP2 bind their mRNA substrate as part of a ribonucleoprotein
complex containing EDCs and favor longer RNA as substrates. This contrasts the
activity of DcpS, which uses short capped oligonucleotides as substrate originating from
degradation by the exosome. In C.elegans it was shown that DCP2 does not associate
with the 5’-cap directly and is not inhibited by cap analogs but rather binds the RNA
11
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Figure 4: Eukaryotic 5’-3’ RNA Degrada-
tion pathway. After deadenylation, proteins of
the family of enhancers of decapping strengthen
the activity of the decapping complex including
DCP1 and DCP2. Decapping leaves a monophos-
phorylated RNA species that is a substrate for
the cellular exonuclease XRN1.
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body with a length requirement of 50 nucleotides39. In addition to the canonical
decapping protein DCP2, other proteins were shown to have decapping activity as
well. Amongst those is NUDT16, which was shown to work on other subsets of RNAs
compared to DCP240;41. Only recently, NUDT3 was identiﬁed to possess mRNA
decapping activity on substrates modulating cell migration42. Interestingly, NUDT16,
NUDT3 and DCP2 (NUDT20) all belong to the same family of Nudix hydrolases.
After decapping, the RNA body is subject to exonucleolytic cleavage by the nuclease
XRN1 that is localized in the cytoplasm of cells (Figure 4). Another member of the
XRN family, namely XRN2 (Rat1) is mainly nuclear. Both proteins are Mg2+-dependent
5’-3’ exoribonucleases acting on single-stranded, unstructured, 5’- monophosphorylated
RNAs43. Capped RNAs or RNAs bearing 5’-hydroxyl or 5’-triphosphate groups renders
them as unsusceptible to degradation by XRN144. By deleting over 40 components
of the mRNA processing pathways, Sun et al. identiﬁed that XRN1 alone leads to an
imbalance between RNA synthesis and degradation. Thereby, XRN1 was suggested to
be a key factor contributing to the buﬀering of mRNA levels45.
1.2.1.4 mRNA quality control
In the cytoplasm, multiple adaptor proteins are able to distinguish aberrant from
normal mRNAs targeting them for degradation. mRNAs with premature translation
termination codons are recognized by the Upf proteins in a process called nonsense-
12
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mediated decay (NMD). After recognition, these proteins are targeted for deadenylation
followed by 3’-5’ degradation by the exosome complex, or decapping and degradation by
XRN146. In yeast, stalled ribosomes causing a pause during elongation are recognized
by the proteins Hbs1 and Dom34. These mRNAs are then targeted for endonucleolytic
cleavage in a process called No-Go decay (NGD)47. Hbs1 and Dom34 are paralogs
of the eukaryotic release factors 1 and 3 (eRF1 and eRF3), respectively where Hbs1
was suggested to recognize the stop codon in the A site of the ribosome and Dom34
to display endonuclease activity48. This ﬁnding however could not be supported in
recent reports49. After an initial cleavage, the mRNA body is degraded by XRN1
and the exosome complex. When stop codons are missing, the Ski complex identiﬁes
those stalled ribosomes and engages the cytoplasmic exosome for RNA turnover by the
Non-stop decay (NSD) pathway50.
Intergenic regions that are erroneously transcribed by RNA polymerase II are as well
rapidly degraded in the nucleus by the actions of the TRAMP complex through adding of
short poly(A) tails and subsequent degradation by the exosome complex17. Additionally,
in a process called unfolded protein response (UPR), mRNA levels are reduced when the
amount of newly synthesized proteins exceeds the folding capacity of the ER. Inositol-
requiring enzyme 1 (IRE1) promotes this in a process called regulated IRE-1-dependent
RNA decay (RIDD), where ER-associated mRNAs are degraded to reduce the load
of freshly generated proteins51. However, the products of IRE-1-mediated cleavages
contain 2’3’-cyclic phosphates that could potentially be recognized as harmful aberrant
RNA species by the innate immune system52.
1.2.1.5 Similarities in eukaryotic and bacterial mRNA degradation
New discoveries suggest unappreciated similarities between pro- and eukaryotic RNA
degradation. For long time it was thought that RNA molecules and proteins involved in
the RNA degradation pathways diﬀer a lot between both kingdoms. One reason for this
notion is the quite diverse chemical structure and organization of RNA molecules in
bacterial and eukaryotic cells. Eukaryotic mRNAs are protected by the 5’-cap structure
connected by an unusual 5’-5’ triphosphate linkage. In contrast, bacterial mRNA is
protected by a 5’-triphosphate group and miss additional post-transcriptional chemical
modiﬁcations on the RNA 5’-end. Additionally, the 3’-end of eukaryotic mRNAs is
elongated by the post-transcriptionally added poly(A) tail. Bacterial mRNA commonly
ends with a stem loop. Moreover, the 5’-cap structure and poly(A) tail of eukaryotic
mRNA are bound by proteins like the eukaryotic translation initiation factor 4F (eIF4F)
and PABP, respectively. Both proteins can interact with each other forming a closed
13
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loop. Bacterial mRNA is not complexed by proteins of that kind.
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Figure 5: Comparison of eukaryotic and bacterial mRNA Degradation pathways.
Despite diﬀerences in the preparation of 3’-ends, the eukaryotic and prokaryotic RNA degradation
shows striking commonalities in regard of 5’-processing involving proteins of the same protein
family namely the Nudix hydrolase family.
The long-standing model for RNA degradation in bacteria comes mostly from studies
in E.coli, which contains several 3’-exonucleases and endonucleases. The stem-loop
structure at the 3’-end of bacterial mRNA protects it from 3’-exonucleolytic cleavage
and therefore it was thought that degradation needs to be initiated with endonucleolytic
cleavage. This model was supported by the ﬁnding that the endonuclease RNase E seems
to play a general role in bacterial mRNA turnover53. However, this model was challenged
by the discovery of polyadenylation of bacterial mRNA and its major importance for
RNA degradation54. Similar to the TRAMP complex - the nuclear exosome regulator
in eukaryotes - a bacterial poly(A) polymerase transiently adds adenosines to the 3’-end
of RNAs. This short poly(A) tail renders it susceptible to 3’-exonucleolytic cleavage
14
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by PNPase (Figure 5) which requires single-stranded RNA to initiate cleavage55. The
PNPase complex is structurally related to the eukaryotic exosome complex. Besides
commonalities in 3’-5’ degradation between pro- and eukaryotes, discovery of an addi-
tional mRNA decay pathway in bacteria shows similarities to eukaryotic degradation
pathways. The RNA pyrophosphorylase RppH is able to dephosphorylate the bacterial
5’-PPP RNA56;57. This reaction is very similar to the eukaryotic process of decapping
(Figure 5). Notably, the eukaryotic decapping enzyme DCP2 and the bacterial pendant
RppH belong to the family of Nudix hydrolases, suggesting an evolutionary conserved
mechanism. Both, the eukaryotic and bacterial reactions yield a monophosphorylated
RNA as product, which can be further processed by 5’-3 exonucleases: XRN1 in eu-
karyotes or RNase J or E in bacteria, both of which can only use monophosphorylated
substrates for degradation58.
Despite these striking similarities in bacterial and eukaryotic mRNA degradation,
notable diﬀerences remain. The 3’- and 5’-terminal degradation processes, including
deadenylation, decapping and exonuclease cleavage, dominate in eukaryotic cells whereas
endonucleolytic cleavage still plays the major role in bacteria. The limited activity of
endonucleases in eukaryotic cells is much more restrained and shows high speciﬁcity
in comparison to endonucleases in bacteria. Moreover, the poly(A) tails play distinct
roles in pro- and eukaryotes. Contrary to eukaryotic poly(A) tails, which mainly serve
as stabilizing features of the RNA molecules regulating their half-lives, the bacterial
polyadenylation has solely destabilizing function and initiates 3’-degradation.
1.2.2 Degradation of RNA Polymerase I transcripts
The maturation of ribosomes requires more than 170 proteins and 70 snoRNAS. A
mature ribosome is then assembled from 82 ribosomal proteins and the four rRNAs59.
Three out of the four rRNAs are produced from one single transcript by endo- and
exonucleolytic cleavage reactions. Therefore, the removal of the ETS and ITS from
the longer rRNA precursor produces a huge amount of nuclear junk RNA due to the
high production rate of ribosomes. Degradation of these RNAs therefore requires most
of the RNA degradation machinery. The resulting ETS and ITS rRNA fragments as
well as defective pre-ribosomes are modiﬁed by the nuclear TRAMP complex, thereby
stimulating exosome mediated RNA degradation (Figure 6).
Involvement of the TRAMP complex was discovered in yeast mutants by David Tollervey
where nuclear export of rRNAs was blocked. In these strains, pre-rRNAs were rapidly
degraded and polyadenylated species of the rRNAs were detected. Moreover, deletion
of a member of the TRAMP complex suppressed polyadenylation and prohibited
15
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Figure 6: Degradation of RNA Polymerase I transcripts. Nuclear surveillance pathways
including the TRAMP complex remove cleavage and processing products of the rRNA maturation
pathway. In the cytosol, defective 18S and 28S rRNA transcripts are recognized and ﬁnally
degraded by the exosome complex. Ribophagy removes whole ribosomes under starvation
conditions.
degradation60. After being exported to the cytoplasm and assembled into ribosomal
subunits, the rRNAs are very stable and degradation is essentially undetectable.
Interestingly, there seems to be a cytoplasmic rRNA quality control pathway that
controls if rRNAs are still functional. In an elegant study in yeast, LaRivie`re et al.
mutated sites important for ribosome function namely in the 25S peptidyl transferase
center and the 18S decoding sequence. This resulted in a decrease in levels of those
rRNAs whereas levels of rRNAs containing mutations in non-conserved positions stayed
constant61. The cellular discrimination of functional and non-functional rRNAs led to
the discovery of the non-functional rRNA decay (NRD) pathway. Turnover of the 18S
rRNA employs Hbs1 and Dom34, the same protein complexes used in the mRNA No-Go
decay pathway (Figure 6)62. Degradation of 25S rRNA remains more enigmatic since
the RNA itself seems to be degraded by the exosome complex whereas the Ski complex
is indispensable. Thus, how the 25S rRNA is recruited to the exosome is still unclear.
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In addition, monitoring green ﬂuorescent protein-fused ribosomal proteins revealed that
under starvation conditions ribosomes were targeted and degraded in the vacuole in
an autophagy-dependent manner. Because of the analogy to the autophagy pathway,
this process has been named “ribophagy” (Figure 6). In a genetic screen the ubiquitin
protease Ubp3 and its activator Bre5 were found to be required for the packaging of
ribosomes in the autophagosome or their fusion to the vacuole63.
17
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1.2.3 Degradation of RNA Polymerase III transcripts
Knowledge of surveillance of RNA Pol-III transcripts (5S rRNA, U6 snRNA and tRNAs)
is more limited. However, comparable to RNA Pol-I transcripts, RNA Pol-III transcripts
are also under surveillance by the TRAMP complex in the nucleus. First evidence came
from a study identifying that the hypomethylated tRNAi
Met is polyadenylated and
degraded by the exosome64.
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Figure 7: Degradation of RNA Polymerase III transcripts. tRNAs with processing
defects are recognized by the nuclear TRAMP complex leading to degradation by the nuclear
exosome complex.
Besides this nuclear pre-tRNA surveillance, mature hypomodiﬁed tRNAs like tRNAVal(AAC)
lacking two speciﬁc methylations are rapidly degraded by a process called rapid tRNA
decay (RTD) pathway which is independent of the TRAMP complex65 but employs a
5’-degradation pathway by the proteins XRN2 and XRN1 (Figure 7)66.
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2. Nucleic Acid Immunity
2.1 Introduction to Nucleic Acid Immunity
The innate immune system is considered to be simple and non-speciﬁc and in recent
years major discoveries led to tremendous advances in the ﬁeld of innate immunity.
All forms of life installed complex mechanisms in order to detect pathogens, in particular
foreign genetic material. Recent advances include the identiﬁcation of pathways that are
restricting the spread of pathogen-derived nucleic acids including the identiﬁcation of
pattern recognition receptors, nucleic acid restriction factors and the turnover of nucleic
acids. These processes are integral parts of a nucleic acid-targeting defense system,
which can be termed nucleic acid immunity (Figure 8)67.
Nucleic Acid TurnoverPattern Recognition Receptors Restriction Factors
Nucleic Acid Immunity
Toll-like Receptors
RIG-I-like Receptors
cGAS
NOD-like Receptors
AIM2
IFIT Proteins
APOBEC Proteins
OAS Enzymes
PKR
ADAR1
TREX1
DNase I
DNase II
RNase H2
Exosome Complex
Figure 8: Nucleic Acid Immunity is shaped by pattern recognition receptors, restriction
factors and nucleic acid turnover
Pattern recognition receptors (PRRs) are germline-encoded sensors that detect molecules
bearing features that mark them as non-self as for instance foreign nucleic acids. They
can be divided in nucleotide-binding-oligomerization domain (NOD) -like receptors
(NLRs), which sense viral PAMPs and cellular stress, retinoic acid inducible gene I
(RIG-I)-like receptors (RLRs) sensing RNA, Toll-like receptors (TLRs), (absent in
melanoma 2) AIM2-like receptors (ALRs) that sense DNA, and cyclic GMP-AMP
synthase (cGAS). Whereas PRRs elicit a broad range of eﬀector functions by activating
signaling cascades, nucleic acid restriction factors have a direct inhibitory eﬀector
function. Restriction factors include interferon induced proteins with tetratricopeptide
repeats (IFIT) proteins, protein kinase R (PKR), apolipoprotein B mRNA editing
enzyme (APOBEC), double-stranded RNA-speciﬁc adenosine deaminase (ADAR) or
2’-5’-oligoadenylate synthetase (OAS) enzymes. The third part includes proteins of
nucleic acid turnover pathways, which regulate the abundance of nucleic acids. This
group includes nucleases like DNase II, three prime repair exonuclease 1 (TREX1), the
exosome complex, SAM domain and HD domain-containing protein 1 (SAMHD1), and
RNase H2.
The importance of all three parts becomes apparent in rare monogenetic inﬂammatory
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disorders like type I interferonopathies where monogenic defects in PRRs, restriction
factors or nucleases result in autoimmune and autoinﬂammatory diseases. Therefore,
nucleic acid immunity has fundamental implications for human health and disease.
2.2 Immune sensing receptors
The paradigm of pattern recognition introduced by Charles Janeway in the late 1980ies
revolutionized our understanding of the immune system. In the introductory words for
the Cold Spring Harbor Symposium on quantitative biology, Janeway hypothesized in a
conceptual paper that infections are detected by germline-encoded pattern recognition
receptors (PRRs) of the innate immune system. These receptors should be able to
sense molecules of microbial origin so called pathogen-associated molecular patterns
(PAMPs)68. At ﬁrst, Charles Janeway’s ingenious insights did not catch a lot of
attention, however remarkably major parts of his conceptual work turned out to be
correct.
By now we know that mammalian cells are equipped with a deﬁned set of receptors that
are able to detect very diﬀerent pathogenic nucleic acids derived from diﬀerent classes
of viruses. Following the sensing of nucleic acids, an immune response is initiated by
the induction of cytokines, chemokines and the expression of antiviral genes.
As a ﬁrst milestone, Isaacs and Lindenmann could demonstrate that foreign nucleic
acids are able to induce the antiviral cytokine type I interferon69;70. But only three
decades later, after Jules Hoﬀmann found that the Drosophila protein Toll plays a
role in antifungal defense71, the mammalian Toll homolog was discovered as the ﬁrst
bona-ﬁde mammalian PRR. Indeed this protein showed an immune function and led
to the expression of antiviral cytokines72. Several additional members of the family
of Toll-like receptors (TLRs) were identiﬁed. The identity of the ﬁrst TLR ligand was
discovered one year later by Paul Godowsky and colleagues, who showed that crude
extracts of the bacterial constituent lipopolysaccharide (LPS) led to a direct response
of TLR273. The ﬁrst pattern recognition receptor shown to detect foreign nucleic-acids
was the cell-type speciﬁc TLR9 (Figure 9), which senses unmethylated CpG motifs
in DNA74. Besides TLR9, other Toll-like receptors were identiﬁed to sense nucleic
acids. Amongst those are TLR3 a sensor of double-stranded RNA75 and TLR7 and
TLR8 sensing RNA degradation products like nucleosides or short polynucleotides76.
Those endosomal TLRs induce the expression of pro-inﬂammatory cytokines and type I
interferons via the signaling adapter molecules TIR-domain-containing adapter-inducing
interferon-β (TRIF)/TANK-binding kinase 1 (TBK1) (in case of TLR3) or myeloid
22
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diﬀerentiation primary response 88 (MYD88) (in case of TLR7, TLR8, and TLR9)
thereby activating the transcription factors interferon regulatory factor 3/7 (IRF3/7) or
nuclear factor ’kappa-light-chain-enhancer’ of activated B-cells (NFκB) (Figure 9).
TLR3 TLR7 TLR8 TLR9
Rnase?
TRIF MYD88
IRF3/7 NF-kB
MAVS
TBK1
RIG-I MDA5
RNA Pol III
AIM2
ASC
CASP1
cGAS STINGcGAMP
pro-IL-1β IL-1β
PPP
AT-rich DNA
PPP
Endosome Cytosol
Nucleus
Type I Interferon
Pattern Recognition Receptor
Signaling Adapter
DNA
RNA
Figure 9: Pattern recognition receptors important for nucleic acid immunity. Diverse
ligands are sensed by a very distinct repertoire of receptors in the endosome or cytoplasm of
cells. Sensing of foreign nucleic acids results in the activation of signaling cascades and the
induction of type I interferons.
In 2004, the pattern recognition receptors RIG-I and melanoma diﬀerentiation antigen
5 (MDA5) were identiﬁed77. RIG-I was identiﬁed to sense blunt-ended RNA with 5’-
triphosphate ends78;79. In addition, RIG-I ligands can originate from AT-rich templates
used by RNA polymerase III yielding 5’-triphosphorylated double-stranded RNA80.
MDA5 recognizes long double-stranded RNA generally not present in healthy cells.
Both, RIG-I and MDA5 engage with the signaling adapter protein mitochondrial
antiviral-signaling protein (MAVS) leading to the expression of type I interferons, pro-
inﬂammatory cytokines and ultimately in the expression of interferon stimulated genes
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(ISGs) (Figure 9).
Moreover, Ju¨rg Tschopp discovered that the inﬂammasome, a multiprotein complex,
is able to induce the caspase 1-dependent secretion of pro-inﬂammatory cytokines like
interleukin-1 (IL-1)81. One activator of the inﬂammasome is the sensor AIM2 that
detects cytosolic DNA thereby activating the inﬂammasome and leading to a release of
bioactive IL-1β (Figure 9)82.
Since the inﬂammasome did not result in the induction of type I interferons, but
yet this response was observed when DNA was delivered into cells, it was clear that
an additional sensing pathway needs to be involved in the detection of cytoplasmic
DNA. In 2012, James Chen discovered the DNA binding enzyme cGAS83. Upon
ligand engagement, cGAS synthesizes the cyclic second messenger cyclic guanosine
monophosphate–adenosine monophosphate (cGAMP) that in turn activates stimulator
of interferon genes (STING) to induce expression of type I interferons (Figure 9)84.
The repertoire of these diverse receptors that are positioned in diﬀerent subcellular
compartments allow the cell to swiftly and appropriately respond to virus infections.
While the receptors are distinct in aﬃnity to the diverse ligands, they overlap in their
ability to engage signaling pathways that culminate in the expression of pro-inﬂammatory
cytokines and type I interferons.
2.3 Discrimination of self and non-self RNA
The identiﬁcation of pattern recognition receptors was an essential requirement to
understand how the cell discriminates pathogenic nucleic acids from cellular nucleic
acids. In a special issue of the Journal of Interferon & Cytokine Research, we review
the principles underlying the discrimination of self and non-self nucleic acids. First, we
provide an overview of the discriminative chemical properties of cellular and viral nucleic
acids. Then, the current literature on RNA sensing is summarized with a spotlight on
the discrimination of these diﬀerential RNA features and modiﬁcations leading to a
terminal restriction of speciﬁcally viral nucleic acids.
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Discrimination of Self and Non-Self Ribonucleic Acids
Anna Gebhardt,* Beatrice T. Laudenbach,* and Andreas Pichlmair
Most virus infections are controlled through the innate and adaptive immune system. A surprisingly limited
number of so-called pattern recognition receptors (PRRs) have the ability to sense a large variety of virus
infections. The reason for the broad activity of PRRs lies in the ability to recognize viral nucleic acids. These
nucleic acids lack signatures that are present in cytoplasmic cellular nucleic acids and thereby marking them as
pathogen-derived. Accumulating evidence suggests that these signatures, which are predominantly sensed by a
class of PRRs called retinoic acid-inducible gene I (RIG-I)-like receptors and other proteins, are not unique to
viruses but rather resemble immature forms of cellular ribonucleic acids generated by cellular polymerases.
RIG-I-like receptors, and other cellular antiviral proteins, may therefore have mainly evolved to sense non-
processed nucleic acids typically generated by primitive organisms and pathogens. This capability has not only
implications on induction of antiviral immunity but also on the function of cellular proteins to handle self-
derived RNA with stimulatory potential.
Keywords: ribonucleic acid sensing, antiviral mechanisms, interferon, MDA5, RIG-I, PRR
Introduction
The host immune system is constantly encounteringpathogen invasion. Viruses, the most abundant patho-
gens on earth, can infect eukaryotes and prokaryotes and
require the supportive environment of the cell to proliferate
and spread. For this reason, organisms evolved barriers in-
cluding the innate and adaptive immune system to suppress
growth of pathogens. Protection against viral infections is to
a large extent mastered by the innate immune system, which
is able to sense incoming virus particles, viral proteins, viral
replication products, and changes in the general integrity of
the cell (Isaacs and Lindenmann 1957; Rassa and Ross
2003; Sancho and Reis e Sousa 2013). As a result, the or-
ganism mounts an appropriate antiviral response that im-
pairs virus growth and allows virus clearance.
Activation of the antiviral innate immune system is
characterized by secretion of antiviral cytokines, particu-
larly type I interferons (IFN-a/b). These cytokines were
identiﬁed by Isaacs and Lindenmann (1957) who demon-
strated that cells secrete antiviral factors upon exposure to
heat inactivated viruses. The main stimulatory agent was
identiﬁed to be nucleic acids that are delivered through the
viral infection process (Goubau and others 2013). Viral
replication greatly enhances the abundance of stimulatory
nucleic acids and thereby regulates the magnitude of the
response (Rehwinkel and others 2010; Weber and others
2013). Both, viral RNA and DNA (vRNA/DNA) can stim-
ulate pattern recognition receptors (PRRs) and recently
molecular principles underlying the basis for detecting
viruses and immune-stimulatory nucleic acids were dis-
covered (Schlee 2013; Ahmad and Hur 2015). Besides ac-
tivation of the innate immune system, viral nucleic acids
modulate the activity of general cellular machineries such as
protein translation, RNA degradation, or cell death (Fig. 1).
At the same time viral nucleic acids are directly targeted by
cellular proteins with antiviral functions. Thus, it becomes
more and more evident that the innate immune system is not
only a blunt alarm system that reacts to a single stimulus. It
rather consists of a highly sophisticated network of proteins
that target pathogen-derived nucleic acids. Importantly, the
innate immune system has dramatic impact on the cellular
and organismal level and its activation has to be modulated
in a very tight manner. In this regards, the discrimination
between ‘‘pathogen derived’’ and ‘‘host’’ nucleic acids is of
central importance.
In this review we will focus on the features of RNAs that
are in place to discriminate between self and non-self
nucleic acids. Viral nucleic acids can be sensed by their
localization in nucleic acid free organelles (such as endo-
somes), and by their chemical modiﬁcations and secondary
structures. Considering current knowledge, it appears that
large parts of the cellular sensing mechanisms are targeting
‘‘missing-self’’ modiﬁcations rather than nucleic acids
speciﬁc to a certain pathogen. This concept is reminiscent of
the adaptive immune system that is also predominantly
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targeting missing-self structures and has proven to work
well to protect against a wide range of invading pathogens.
Generation and Properties of Cellular RNA
To explain how intruding vRNAs are sensed by the innate
immune system it is important to consider basic processes
that are in place to generate cellular nucleic acids in higher
eukaryotes. Generation of cellular RNAs is limited to the
nucleus and mitochondria. The cytoplasm, however, is the
compartment in which most RNAs are active and it is
the site that is best surveyed by PRRs. Three cellular RNA
polymerases (Pol-I, Pol-II, and Pol-III) are responsible for
the generation of different types of RNAs. In a ﬁrst step
these polymerases generate precursor transcripts that carry a
5¢ triphosphate (5¢ PPP) group on their RNA (Fig. 2).
However, before translocation to the cytoplasm, the 5¢ end
of these transcripts gets variably modiﬁed. In case of Pol-II
transcripts, such as messenger RNA (mRNA) and most
small nuclear RNAs (snRNAs), a guanosine nucleotide is
coupled to the 5¢ PPP group of the nascent RNA and forms
the 5¢ cap structure (McCracken and others 1997; Furuichi
and Shatkin 2000). Moreover, the 5¢ cap structure is further
modiﬁed by a methylation mark at the N7-position of the
guanosine (N7 methylation), the 2¢O-position of the ﬁrst (to
generate Cap1 mRNA) and possibly also on the second ri-
bose (Cap2 mRNA) (Byszewska and others 2014). All these
modiﬁcations are co-transcriptionally added to the newly
generated transcript (Topisirovic and others 2011) and are
important for further processing and transport to the cyto-
plasm (Kohler and Hurt 2007; Muller-McNicoll and Neu-
gebauer 2013). Lower eukaryotes, such as yeast, which
appear not to use an IFN-based antiviral defense system,
lack 2¢O methylation on capped RNA (Byszewska and
others 2014).
Ribosomal RNAs (rRNAs) are transcribed by Pol-I as a
45S-pre-rRNA with a 5¢ PPP-RNA structure. After cleavage
of the precursor into 28S, 18S, and 8S, rRNA, a 5¢ mono-
phosphate (5¢ P) is obtained on the individual RNAs (Fig. 2)
(Drygin and others 2010). Similarly, Pol-III generates
a subset of additional RNAs comprising transfer RNA
(tRNA), some small nucleolar RNA (snoRNAs), 5S rRNA,
7SK RNA, and U6 snRNA (Hopper 2013; Kirchner and
Ignatova 2015). Like Pol-I transcribed rRNAs, tRNAs
bear a 5¢ P after cleavage of a 5¢ oligonucleotide. U6 snRNA
and 7SK RNA are not cleaved but bear a 5¢ gamma-
monomethyltriphosphate (5¢ PmPP-RNA) after processing
(Singh and Reddy 1989).
In addition to the 5¢ end modiﬁcations, host RNAs are
highly modiﬁed on internal nucleotides (Sarin and Leidel
2014; Rosenthal 2015). However, the function of only a few
modiﬁcations has been elucidated to date. Deamination of
adenosines to inosines (A-to-I) by the RNA editing enzyme
adenosine deaminase acting on RNA 1 (ADAR1), for in-
stance, was recently shown to destabilize stem loop struc-
tures of Alu elements located in the 3¢ untranslated region
(UTR) of some mRNAs (George and others 2014). Re-
petitive Alu elements form double-stranded (ds) RNA
structures that can stimulate IFN responses (Athanasiadis
and others 2004; Levanon and others 2004). Deamination of
such Alu elements in the 3¢ UTR of mRNA leads to desta-
bilization of dsRNA and reduced activation of the innate
immune system (Hartner and others 2009). It still has to be
determined how speciﬁcity to certain adenines is mediated
and to what extent such deamination events also affect
coding regions of proteins by accumulating mutations, po-
tentially leading to protein misfolding. However, genetic
evidence clearly shows that lack of ADAR1 is embryoni-
cally lethal in mice presumably due to elevated levels of
dsRNA (Rice and others 2012). Deleting critical innate
immune signaling molecules [eg, mitochondrial antiviral-
signaling (MAVS) protein (also called IPS-1, VISA, or
Cardif)] in these mice reduces this phenotype clearly sug-
gesting that inability to deaminate RNAs on internal resi-
dues results in an IFN-dependent pathology (Liddicoat
and others 2015; Pestal and others 2015; George and
others 2016).
Another type of RNA that is prominently modiﬁed on
internal residues are tRNAs. Internal modiﬁcations, such as
ribose 2¢O methylation on guanosine at position 18 and 34,
have been shown to be important to dampen potential
immune-stimulatory activity of tRNAs (Gehrig and others
2012; Jockel and others 2012; Kaiser and others 2014). It
is quite likely that other not yet deﬁned chemical modiﬁ-
cations exist to prevent activation of the innate immune
system.
Besides chemical modiﬁcations of RNA it is important to
note that most RNAs are bound by RNA-binding proteins
under steady-state conditions. Proteins associating to RNA
can either contribute to activation or inhibition of the innate
immune system. Viral proteins such as the E3L protein of
Vaccinia virus, the nonstructural protein 1 (NS1) protein of
Inﬂuenza A virus (IAV) or B2 of Flock house virus are
binding dsRNA and can reduce the potential of stimulatory
RNA likely by restricting accessibility to PRRs (Lingel and
others 2005; Ayllon and Garcia-Sastre 2015). Similarly, the
Effects on 
Cellular Machinery
Viral 
Nucleic Acid
Direct Viral Targeting
Inhibition of 
Virus
Sensor Sensor
Induction of 
Cytokines
Effector
Activation
Increase in Expression
Effect
FIG. 1. Viral nucleic acids trigger a
variety of events that are governed by a
variety of speciﬁc cellular sensor pro-
teins. Despite that these sensor proteins
can identify the same type of viral nu-
cleic acid, the antiviral and cellular ef-
fects are diverse. A key function of viral
nucleic acids is the induction of cytokines,
which regulate expression of many anti-
viral proteins, including sensor or effector
proteins with afﬁnity for the same viral
nucleic acids. Engagement of these pro-
teins with viral nucleic acid leads to
changes in biological activity of cellular
functions or in direct viral inhibition.
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cellular RNA binding protein laboratory of genetics and
physiology 2 (LGP2) reduces the stimulatory potential of
certain RNAs (Venkataraman and others 2007), presumably
by steric interference with activation of cellular PRRs
(Yoneyama and others 2005; Saito and others 2007).
However, LGP2 has also been shown to promote induction
of IFN by a subset of viruses (Venkataraman and others
2007). Cellular RNA helicases can prepare viral ligands to
be better sensed by effector proteins of the innate immune
system (Ahmad and Hur 2015; Yao and others 2015). This
is likely happening through displacement of other RNA
binding proteins from the stimulatory RNA or due to
changes in the secondary structure of the RNA. In recent
years, a surprisingly high number of cellular helicases in-
cluding DEAD-box protein (DDX) DDX1 (Zhang and
others 2011a), DDX3 (Oshiumi and others 2010; Thulasi
Raman and others 2016), DEAH-box helicase DHX9
(Zhang and others 2011b), DDX17 (Moy and others 2014),
DDX60 (Miyashita and others 2011), and others, have been
shown to be involved in induction of type I IFN. These
proteins mostly do not directly bind to signaling molecules
of the canonical IFN pathway but appear to have important
accessory functions to properly activate the innate immune
system. However, the contribution of RNA binding proteins
to modulate innate immune responses can be diverse and
needs to be characterized on an individual level.
Features of vRNA
Viruses often use relatively simple replication machin-
eries resulting in RNAs that are only partially processed and
therefore resemble a premature state of cellular RNAs. A
number of PRRs evolved to sense such unprocessed RNA.
The simplest evidence for this is the ability of cells to sense
5¢ PPP-RNA, which constitutes the most basic product of
RNA polymerases, through the cellular PRR retinoic acid-
inducible gene I (RIG-I) (Hornung and others 2006; Pichl-
mair and others 2006). Delivery of 5¢ PPP-RNA into the
RIG-I Ligands MDA5 Ligands
Non-Stimulatory Cellular RNA
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me
P
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P P P
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Higher-Order RNA Structure
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g
Cleavage
Cleavage
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FIG. 2. Stimulatory and nonstimulatory RNAs in cells. This schematic provides an overview of the main proportion of
cellular RNAs and cytoplasmic RIG-I and MDA5 stimulatory RNAs. Host RNAs are synthesized by RNA polymerase I–III
(Pol-I, Pol-II, and Pol-III) in the nucleus. The RNAs are generated as a precursor RNA bearing a 5¢ triphosphate group,
which is extensively modiﬁed in the nucleus before getting transported to the cytoplasm where they perform their biological
function. snRNAs are further modiﬁed in the cytoplasm and reimported to the nucleus. Nonstimulatory cytoplasmic cellular
RNA (blue box) are not activating cytoplasmic PRRs. Speciﬁc viruses can introduce different types of stimulatory RNA
during the infection process. These RNAs often resemble premature forms of cellular RNA and can be classiﬁed into RIG-I
(green box) and MDA5 ligands (orange box). AAA, poly(A) tail; DI genomes, defective interfering genomes; dsRNA,
double-stranded ribonucleic acid; MDA5, melanoma differentiation-associated protein 5; me, methyl group; mRNA,
messenger RNA; P, phosphate group; PRR, pattern recognition receptor; RIG-I, retinoic acid-inducible gene I; rRNA,
ribosomal RNA; snRNA, small nuclear RNA; tRNA, transfer RNA.
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cytoplasm activates type I IFN expression in an RIG-I-
dependent manner. Many negative strand RNA viruses such
as orthomyxo-, paramyxo-, and most bunyaviruses generate
5¢ PPP-RNA constituting either the genomic RNA, repli-
cation by-products [eg, complementary RNA (cRNA)], or
short subgenomic RNAs (Pichlmair and others 2009; Gou-
bau and others 2013; Habjan and Pichlmair 2015). Inter-
estingly, most viruses that generate 5¢ PPP-RNA express
auxiliary factors (eg, NS1 of IAV, V protein of Measles
virus, etc.) that actively impair activation of the innate im-
mune system (Versteeg and Garcia-Sastre 2010). Viruses
that do not express such dedicated viral proteins, commonly
process the 5¢ RNA terminus to escape immune surveil-
lance. Bornaviruses and a subset of Bunyaviruses including
Crimean–Congo hemorrhagic fever virus, for instance, em-
ploy a 5¢ trimming event as part of their replication strategy
(Schneider and others 2007; Habjan and others 2008).
Thereby the terminal nucleotides are cleaved by a viral
nuclease leaving a 5¢ P on the genomic RNA. Picorna- and
caliciviruses shield their genomic 5¢ PPP-end with the co-
valently linked VPg protein (Flanegan and others 1977; Lee
and others 1977; Habjan and others 2008), which impairs
binding of cellular PRRs to the 5¢-end of vRNAs.
Viruses, such as ﬂavi-, corona-, pox-, and reoviruses
encode their own capping enzymes to generate 5¢ capped
mRNA (Decroly and others 2012). In addition to capping,
these viruses independently evolved proteins that methylate
the ﬁrst ribose at the 2¢O-position to generate RNA that
resembles cellular mRNA modiﬁcations, indicating a strong
selective pressure to favor this modiﬁcation. Interestingly,
viruses that lack the ability to methylate the 2¢O position on
the ﬁrst ribose are sensed by the innate immune system
(Dafﬁs and others 2010; Habjan and others 2013; Schuberth-
Wagner and others 2015). Orthomyxo- and bunyaviruses
employ an alternative approach to gain a fully processed cap
structure called ‘‘cap-snatching.’’ The ﬁrst 10–13 nucleo-
tides of a cellular mRNA are fused to the 5¢ end of a vRNA,
which thereby acquire cellular marks that allow evasion
from host sensing mechanisms (Dias and others 2009; De-
croly and others 2012; Reich and others 2014; Koppstein
and others 2015).
In addition to 5¢-end modiﬁcations vRNA has structural
properties that allow discrimination from cellular RNAs. In
particular, RNA double-strandedness of certain length is a
feature that is often sensed by PRRs. Such long dsRNAs are
generated by genome replication of dsRNA viruses or as
replication by-products of many single-stranded (ss) RNA
viruses. Even DNA viruses such as pox- and herpes viruses
generate dsRNA through convergent transcription (Weber
and others 2006; Feng and others 2012).
In the last years, genomic viral secondary structure ele-
ments generating portions of double-strandedness on ssRNA
genomes like panhandle structures or stem loops have been
shown to be recognized by antiviral mechanisms (Schlee
and others 2009; Resa-Infante and others 2011; Moy and
others 2014; Xu and others 2015). Although the underlying
data are very compelling, it is still challenging to explain
how the cell distinguishes viral from cellular dsRNA, par-
ticularly given the well-documented existence of natural
dsRNA (Portal and others 2015) and high frequency of stem
loops commonly found in RNAs of human origin. Different
explanations for the increased immunogenicity of viral nu-
cleic acids are possible: A certain threshold of dsRNA may
have to be reached to activate the innate immune system. The
abundance of vRNAs present in infected cells by far exceeds
the abundance of cellular dsRNA. A threshold model is also
supported by experiments using the poxvirus Modiﬁed Vac-
cinia Virus Ankara (MVA): Although poxviruses naturally
generate dsRNA, a genetically engineered MVA strain that
expresses increased levels of dsRNA shows superior immu-
nogenicity (Wolferstatter and others 2014). Another expla-
nation could be the subcellular localization of dsRNA since
the majority of cellular dsRNA should remain in the nucleus
or membrane covered cytoplasmic virus factories (Mack-
enzie 2005; Paul and Bartenschlager 2015), which cannot be
surveyed by PRRs. Additionally, speciﬁc sequences associ-
ated to viral dsRNAs may contribute to signaling strength.
Interestingly, the presence of double-strand portions within
RNA is not always beneﬁcial for virus sensing. Alphaviruses
exhibit a secondary structural motif within the 5¢UTR, which
prevents binding and activation of innate immune restriction
proteins (Hyde and others 2014). Mechanistically, this high
afﬁnity dsRNA portion may not be accessible to cellular
proteins and therefore most likely evolved as virus counter-
measure against immune surveillance by the immune system
(Hyde and others 2014).
Sensors of Viral or Nonprocessed RNA
A number of germline-encoded receptors have the ability to
sense the presence of viral nucleic acids and initiate a variety
of downstream events aiming at clearance of the invading
pathogen. These receptors can be grouped in respect to their
subcellular localization (endosomal or cytoplasmic), their li-
gand speciﬁcity (DNA, dsRNA, and ssRNA) and their effect
after vRNA engagement (regulators of transcription, transla-
tion, or direct effect on vRNA). Here, we focus on cytoplas-
mic sensors of viral-derived RNAs and refer to other excellent
reviews dealing with sensing in endosomes or of other viral
ligands (O’Neill and others 2013; Cai and others 2014; Hor-
nung and others 2014; Pelka and others 2016; Roers and
others 2016).
RIG-I-Like Receptor-Mediated Recognition
The discovery of the PRR RIG-I by Takashi Fujita’s
laboratory opened a new era in the understanding of RNA
virus sensing (Yoneyama and others 2004) and led to the
identiﬁcation of a class of receptors named RIG-I-like re-
ceptors (RLRs) (Onoguchi and others 2011). The highly
conserved family of RLRs is comprised of three structurally
related proteins named RIG-I, melanoma differentiation-
associated protein-5 (MDA5), and LGP2 (Yoneyama and
others 2005; Onoguchi and others 2011). All members be-
long to the Asp-Glu-Ala-Asp (DEAD) box family and
consist of a RNA helicase domain with ATPase activity and a
C-terminal domain (CTD), which is important to mediate
speciﬁcity to virus-derived nucleic acid sensing (Takahasi and
others 2008). RIG-I and MDA5 accommodate twoN-terminal
caspase activation and recruitment domains (CARDs), which
initiate downstream signaling through CARD-dimerization
with the MAVS protein.
Genetic deletion of RIG-I and MDA5 showed that RIG-I
and MDA5 exhibit speciﬁcity for certain viruses indicating
that distinct nucleic acids are sensed by these receptors.
RIG-I is able to detect viruses of the rhabdoviridae family
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such as Vesicular stomatitis virus and viruses of the para-
myxoviridae family including Newcastle disease virus,
Sendai virus (SeV), and Measles virus. MDA5 detects
viruses of the Picornaviridae family such as Encephalo-
myocarditis virus and Polio virus (Gitlin and others 2006;
Kato and others 2006). Some ﬂaviviruses (eg, Dengue virus,
West Nile virus, and Semliki forest virus) activate both,
RIG-I and MDA5 (Fredericksen and others 2008; Akhry-
muk and others 2016).
In contrast to RIG-I and MDA5, the role of LGP2 is less
well understood particularly since this protein is missing a
CARD. Depending on the experimental system, it was
shown that LGP2 could serve as a negative regulator of RLR
signaling (Saito and others 2007; Venkataraman and others
2007) or activate induction of IFN (Venkataraman and
others 2007). However, more recent studies strengthen the
ﬁnding that LGP2 operates as a positive regulator of MDA5
(Satoh and others 2010; Bruns and others 2014; Uchikawa
and others 2016).
An important property of all RLRs is their ability to in-
teract with dsRNA. However, although it became evident
that binding to dsRNA is important to activate RLRs, RNA
double-strandedness is not always sufﬁcient to induce sig-
naling. Additional requirements on stimulatory RNA, par-
ticularly chemical modiﬁcations, may serve as safeguard to
reduce accidental activation of type I IFN signaling, par-
ticularly if the double-stranded stretch on RNA is only short.
Activation and Downstream Signaling of RLRs
Activation of RIG-I requires ligand binding, a cascade of
regulatory post-translational modiﬁcations and binding of
proteins resulting in the exposure of the CARDs. In unin-
fected cells, RIG-I CARDs and the CTD are constitutively
phosphorylated at Ser8 and Thr170 by Protein Kinase C
alpha/beta and Casein Kinase II (CKII) (Sun and others
2011; Maharaj and others 2012). In the phosphorylated state
RIG-I adopts a ‘‘closed’’ conformation sequestering the
CARDs from signaling due to interactions with the C-
terminal repressor domain. The ATPase activity of the he-
licase domain allows RIG-I to constantly scan RNAs for the
presence of viral motifs and was shown to be a key element
to prevent recognition of self-RNA (Lassig and others
2015). ATP hydrolysis facilitates the release of RIG-I from
self-RNA, while presence of viral motifs detected through
the CTD leads to stalling and activation of RIG-I. Subse-
quently, the constitutive Ser/Thr phosphorylation sites in the
CARDs are removed by serine/threonine-protein phospha-
tase a and g (PP1a and PP1g) resulting in Riplet-mediated
ubiquitination of the CTD. This is followed by dimerization
and a conformational rearrangement of RIG-I leading to the
exposure of CARDs (Oshiumi and others 2013; Peisley and
others 2013), binding of ubiquitin/ISG15-conjugating en-
zyme (TRIM25) to CARD1, and subsequent K63-linked
ubiquitination in CARD2 (Gack and others 2007). After
activation, the CARDs of RIG-I form a helical tetramer in a
lock washer conformation. Multiple lock washer tetramers
form a helical trajectory that allows MAVS ﬁlament as-
sembly along this structure (Wu and others 2014). This re-
sults in clustering of multiple MAVS molecules and
activation of downstream signaling.
In contrast to RIG-I, MDA5 oligomerizes as ﬁlaments in a
head-to-tail fashion along dsRNA to reach high-afﬁnity in-
teractions with long dsRNA ligands (Peisley and others
2011; Berke and others 2012). After oligomerization, the
CARDs of MDA5 point outward of the ﬁlament and oli-
gomerize in structures that can bind to MAVS and activate
downstream signaling (Wu and others 2013). Interestingly,
MDA5 activation is signiﬁcantly increased by LGP2, which
does not contain a CARD itself. Structural analysis showed
that LGP2 binds the end of dsRNAs (very much like RIG-I)
and thereby initiates MDA5 ﬁlament oligomerization on
dsRNA (Uchikawa and others 2016). LGP2 and MDA5 have
been shown to bind similar stimulatory RNAs, which is in
line with cooperative activity of LGP2 in MDA5 activation.
LGP2-precipitated RNAs induce IFN-a/b in a MDA5-
dependent manner providing a functional link between
LGP2 and MDA5 (Deddouche and others 2014).
A key uniting feature of all RLRs is signaling through
MAVS. Under physiological conditions, MAVS is kept in-
active by an autoinhibitory mechanism. Upon binding to
oligomerized CARDs of RLRs, the regions responsible for
downstream signaling including TANK-binding kinase 1
(TBK1)/Interferon regulatory factor 3 (IRF3) and IkB ki-
nase (IKK)/nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) activation sites are exposed and
induce signaling events that result in expression of type I
IFNs and proinﬂammatory cytokines (Shi and others 2015).
Sensing of 5¢ Modifications by RIG-I
RIG-I activation requires two features that co-occur on
one RNA molecule. The ﬁrst essential feature for RIG-I
activation is a chemical modiﬁcation on the 5¢ terminus of
the RNA. The best described 5¢ modiﬁcations that activate
RIG-I are 5¢ tri- and 5¢ di-phosphates (Hornung and others
2006; Pichlmair and others 2006; Goubau and others 2014).
However, more recently it has been shown that RIG-I is also
activated by capped RNA that lack a methylation mark at
the 2¢O ribose position of the ﬁrst nucleotide (Schuberth-
Wagner and others 2015; Devarkar and others 2016). A
conserved residue (Histidine 830) within the CTD of RIG-I
sterically prevents binding of cellular 2¢O-methylated RNA,
and therefore serves as molecular gatekeeper to pertain ac-
tivation by cellular mRNAs. Silencing of the endogenous
cap-speciﬁc mRNA (nucleoside-2¢-O-)-methyltransferase 1
(MTr1) converts nonstimulatory into stimulatory mRNA
and triggers a spontaneous RIG-I-dependent type I IFN re-
sponse (Schuberth-Wagner and others 2015). The second
essential feature for RIG-I activation is a short stretch of
blunt-ended dsRNA. While chemically synthesized 5¢ PPP-
ssRNA is not sufﬁcient to prominently activate RIG-I,
5¢ PPP-dsRNA molecules with the same sequence show
very strong activity (Schlee and others 2009; Schmidt and
others 2009). Reports regarding the minimum length of this
dsRNA stretch range from at least 10 base pairs (bp)
(Schmidt and others 2009; Kohlway and others 2013) to
19 bp (Schlee and others 2009). Experiments transfecting
differently modiﬁed RNA clearly show that 3¢ overhangs at
the 5¢-end are sufﬁcient to impair activation of RIG-I
(Schlee and others 2009) and may even serve as dominant
negative decoy substrate (Marq and others 2011).
Besides dsRNA with 5¢ PPP modiﬁcations, short 5¢ hy-
droxyl (5¢ OH) and 3¢ monophosphoryl (3¢ P) dsRNA
cleavage products of 2-5A-dependent ribonuclease (RNA-
seL) have been proposed to serve as RIG-I ligands (Malathi
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and others 2007, 2010). Although this notion is supported by
many functional data, the exact mechanism of RIG-I acti-
vation is not clear to date, particularly since this appears to
happen in a cell type-dependent manner (Banerjee and
others 2014).
Sensing of RNA in Virus-Infected Cells
Despite formidable progress that allowed deﬁning opti-
mal activation of RIG-I by synthetic ligands much less is
known about the nature of the physiological ligand gener-
ated during virus infections. Many elegant studies aimed to
deﬁne the physiological RIG-I stimulus. Compelling evi-
dence suggests that viral genomic RNA delivered by virus
infection activates RIG-I. Here, we discuss data that support
this notion and also consider questions that still remain to be
answered. Evidence for vRNA being the physiological li-
gand for RIG-I was already provided by Isaacs and Lin-
denmann (1957), who found that cells treated with high
amounts of heat-inactivated viruses activate type I IFN.
More recently this was supported by data that show that
delivery of replication incompetent viral particles activate
RIG-I (Weber and others 2013). Furthermore, shortly after
infection, vRNA of infectious viral particles closely asso-
ciates with mitochondria, which are serving as signaling
hubs for the induction of type I IFN (Liedmann and others
2014). However, the magnitude of an antiviral response
triggered by incoming vRNA appears to be relatively low
and viral replication appears to be required to elicit high
amounts of IFN (Crotta and others 2013; Killip and others
2014). One reason could be insufﬁcient abundance of
stimulatory RNAs, which questions whether incoming viral
nucleic acids are signiﬁcantly contributing to type I IFN
production under physiological conditions.
Genomic vRNA isolated from virus particles and trans-
fected into cells potently stimulates RIG-I (Hornung and
others 2006; Pichlmair and others 2006). This is in agree-
ment with the notion that vRNA isolated from IAV particles
spontaneously forms the so-called panhandle structure. This
structure is formed due to base-pairing of terminal ssRNA
sequences of many negative ssRNA viruses and serves as
promoter for the viral polymerase complex (Hsu and others
1987; Fodor and others 1994; Tiley and others 1994). The
panhandle structure resembles in vitro synthesized blunt
ended 5¢ PPP RNA. In line with RIG-I activation by syn-
thetic ligands, the panhandle thus constitutes a perfect
stimulus for RIG-I activation and explains the very strong
stimulatory activity of isolated vRNA. Interestingly, mis-
matches in the panhandle structure of some IAV strains
disrupt RNA complementarity and results in reduced acti-
vation of RIG-I (Anchisi and others 2016). Such an adap-
tation may therefore represent a viral strategy to evade RIG-
I activation (Anchisi and others 2016). Supporting evidence
that viral genomic RNA stimulates RIG-I comes from ex-
periments using minireplicon systems. vRNA of deﬁned
length generated by the IAV polymerase complex activates
RIG-I (Rehwinkel and others 2010). Interestingly, PPP-
RNA is not only generated by viruses but also by bacteria.
mRNA in bacteria is not capped and intracellular bacteria
such as Listeria and Legionella have been shown to activate
RIG-I (Monroe and others 2009; Abdullah and others 2012).
Although the notion that genomic vRNA is the major
ligand activating RIG-I in virally infected cells is elegant, a
number of additional aspects linked to the replication pro-
cess of viruses complicate this simple model: During viral
replication, vRNA is constantly bound by viral proteins,
which theoretically prevent activation of RIG-I. In case of
many negative strand RNA viruses the viral polymerase
complex is located at the 5¢-end of vRNAs potentially
shielding the terminal PPP group from being sensed by RIG-
I. Indeed, for IAV it has been shown that association of the
polymerase complex to the vRNA polymerase protects from
innate sensing by RIG-I (Weber and others 2013; Liedmann
and others 2014). Variants of the viral polymerase complex
featuring weaker afﬁnity for viral genomic RNAs have re-
duced ability to impair activation of the innate immune
system (Weber and others 2013) suggesting that under
certain conditions vRNAs can be a physiological activator
of RIG-I and that the presence of proteins actively impair
RIG-I activation. Besides a potentially inaccessible 5¢-end,
the relative contribution of the panhandle structure to pro-
vide a dsRNA platform for RIG-I binding is not so clear:
Although isolated genomic RNA of IAV clearly generates
blunt double-stranded ends, the structure of the panhandle
bound to the viral polymerase complex, as it exists in virally
infected cells, adopts a partially single-stranded conforma-
tion (Tiley and others 1994). This notion is supported by
low afﬁnity binding of the negative strand RNA virus
polymerases to the double-stranded panhandle structure
compared to binding to ssRNA (Pﬂug and others 2014;
Gerlach and others 2015). Thus, the panhandle structure
most likely either exists as a ‘‘corkscrew’’ (Neumann and
Hobom 1995; Flick and others 1996) or as a ‘‘fork’’ (Fodor
and others 1994, 1995; Kim and others 1997) structure in
virally infected cells. Both structures presumably only allow
suboptimal activation of RIG-I and it is therefore still not
ﬁnally solved what type of RNA prominently activates RIG-
I in virus infected cells.
A possibility is the activation of RIG-I by viral replication
intermediates or by defective interfering (DI) particles,
which are commonly generated during infections with
viruses including SeV, IAV, and Measles virus (Strahle and
others 2006; Baum and others 2010; Runge and others
2014). Although DI particles are not replicating, they
prominently activate the innate immune system (Killip and
others 2012).
Besides generating stimulatory nucleic acids from viral
templates, RNA-dependent RNA polymerases (RdRP) also
have the ability to use cellular RNA as templates resulting in
the generation of host-derived stimulatory RNAs. Expres-
sion of Simian foamy virus RdRP, for instance, leads to
induction of IFN-b in the absence of viral templates (Ni-
konov and others 2013). In addition, expression of RdRP in
transgenic animals induces a constant IFN response that
leads to increase virus resistance in these animals (Painter
and others 2015). The ability of viral polymerases to gen-
erate cellular RNA copies with IFN inducing capability
indicates that RdRP transcripts feature stimulatory modiﬁ-
cations rather than the actual sequence being sensed by in-
nate immune sensors. Interestingly, the ability to generate
stimulatory RNA from cellular templates has so far only
been shown for RdRPs that are active in the cytoplasm. A
possible explanation for this could be the absence of RNA-
modifying enzymes in the cytoplasm, which does not allow
RNA processing to minimize the stimulatory potential of
RdRP generated RNA.
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Sensing of dsRNAs by MDA5
In contrast to ligands for RIG-I, requirements for MDA5 ac-
tivation are less well understood. MDA5 recognizes long
dsRNA(greater than*0.5 kB) that is normallynot present in the
cytoplasm of uninfected cells (Kato and others 2008). A com-
monly used synthetic activator for MDA5 is poly-I:C, which is
generated through annealing of enzymatically synthesized
poly-I and poly-C homopolymers of undeﬁned length. Al-
though poly-I:C is regarded as dsRNA analog, the structure of
poly-I:C is most likely not a uniform double-strand but may
rather adopt a web-like structure (Pichlmair and others 2009).
Interestingly, similarly synthesized poly-A:U or poly-G:C
have very little stimulatory potential suggesting features as-
sociated with poly-I:C that are not yet well understood.
The best characterized viruses leading to MDA5 activa-
tion are picornaviruses [eg, Encephalomyocardidits virus
(EMCV), Theiler’s murine encephalitis virus, Poliovirus, or
Norovirus] featuring a positive ssRNA genome (Gitlin and
others 2006; Kato and others 2006; Loo and others 2008;
McCartney and others 2008). While RIG-I activating viruses
have the ability to induce PRR signaling through viral ge-
nome recognition, activation of MDA5 by EMCV strictly
requires transcription of the viral genome and generation of a
dsRNA intermediate resulting in a 7.5 kb replicative form of
EMCV (Feng and others 2012; Triantaﬁlou and others 2012).
Furthermore, it is likely that additional replication interme-
diates representing higher order structural RNAs are gener-
ated and sensed by MDA5 (Pichlmair and others 2009).
Unbiased Approaches to Identify
PRR-Associated vRNA
More recently, next generation sequencing was used to
characterize the RNA ligand bound to MDA5 or RIG-I. An
issue with such approaches is that the helicase domain of
RLRs can generally associate with dsRNA and that this
afﬁnity does not directly lead to activation of RIG-I or
MDA5. However, next generation sequencing helped to
identify commonalities and differences in RNA binding
between MDA5 and RIG-I. In Measles virus-infected cells,
for instance, both, MDA5 and RIG-I preferentially bind to
viral AU-rich sequences, particularly in the Measles virus L-
region (Runge and others 2014). However, MDA5 shows
superior enrichment for the Measles virus (+) sense RNA,
while RIG-I preferentially bind to RNA of negative polarity.
In a similar approach, Sanchez David and colleagues used
next-generation sequencing analysis to investigate RNA
precipitated with RIG-I, MDA5, and LGP2 in Measles and
Chikungunya virus-infected cells. The authors showed that
each of the RLRs binds distinct regions of the viral genome.
RIG-I bound speciﬁcally the 3¢UTRof theChikungunya virus
genome and DI genomes of Measles virus, whereas, MDA5
and LGP2 sensed nucleoprotein coding regions of Measles
virus (Sanchez David and others 2016). The shared RNAs
targeted by MDA5 and LGP2 strongly support a functional
relationship between these two PRRs, which is also conﬁrmed
by alternative functional and structural approaches (Goubau
and others 2014) (Uchikawa and others 2016).
In sum, it is evident that distinct RNA species trigger RIG-I
and MDA5 activation. These RNA species may even be ex-
pressed at different time points during the infection process.
Indeed, it was shown that vRNA products generated at dif-
ferent time points after West Nile virus infection sequentially
stimulate RIG-I andMDA5, whereby, RIG-I triggers an early
and MDA5 a later response (Errett and others 2013).
Direct Effectors of Viral Nucleic Acids
Besides RLRs, which have the ability to sense nucleic acids
and regulate transcriptional programs, a set of additional
proteins exist that are binding to speciﬁc viral nucleic acids
(Habjan and Pichlmair 2015). These proteins either have the
ability to regulate cellular processes that are unrelated to
transcription or directly bind and thereby impair the activity of
viral nucleic acids. Often these additional vRNA binding
proteins are inducible by type I IFNs underlining their in-
volvement in antiviral processes. This concept of multiple
cellular proteins associating to a given type of stimulatory
RNA is best illustrated by dsRNA binding proteins (Fig. 3).
dsRNA activates the PRR MDA5, which is activating a
transcriptional program culminating in expression of type I
IFN. Besides MDA5, dsRNA-dependent Protein Kinase R
(PKR) and 2¢-5¢-oligoadenylate synthetase (OAS1) directly
bind dsRNAs. PKR regulates a plethora of antiviral processes
after binding to dsRNA including inhibition of translation
through continuous phosphorylation of eukaryotic initiation
factor 2 alpha (eIF2-a), induction of apoptosis and autophagy
(Kang and Tang 2012), and activation of NF-kB through in-
teracting with the IKK complex (Zamanian-Daryoush and
others 2000). PKR has additionally been linked to regulation
of type I IFN expression (Diebold and others 2003; Gilfoy and
Mason 2007). While this accessory function of PKR is dis-
pensable for RIG-I-dependent responses, IFN induction by
viruses that activate MDA5 appears to be critically relying on
additional activity by PKR (Schulz and others 2010; Wol-
ferstatter and others 2014; Pham and others 2016). After
binding to dsRNA OAS1 generates 2¢-5¢-linked oligoadeny-
lates (2¢-5¢-OA) that serve as second messengers and have the
ability to activate the latent RNAseL. Only after activation,
RNAseL cleaves RNA eventually resulting in cell death
(Chakrabarti and others 2011). Furthermore, vRNAs bind to a
number of DEAD- and DEAH-box helicases, which often
appear to have auxiliary functions to regulate IFN-a/b ex-
pression and also bear direct virus inhibitory function. DDX3,
for instance, has been shown to be important for activation of
the IFN signaling pathway (Oshiumi and others 2010; Gu and
others 2013). DDX3 was also shown to restrict HBV repli-
cation and, thereby, acting as an antiviral effector protein (Ko
and others 2014).
As for dsRNA, 5¢ PPP-RNA, which activates RIG-I, can
associate with additional cellular proteins. Unbiased AP-MS
experiments and follow-up studies using mutational ap-
proaches identiﬁed the interferon-induced protein with tet-
ratricopeptide repeats (IFIT) 1 and -5, which directly
associate with 5¢ PPP-RNA (Pichlmair and others 2011;
Fensterl and Sen 2015). Depending on the exact experimental
setup, IFIT1-deﬁcient mice appear to be more susceptible to
5¢ PPP-RNA generating viruses such as Vesicular stomatitis
virus (Pichlmair and others 2011). However, while RIG-I
activation requires dsRNA, IFIT proteins speciﬁcally bind
only ssRNAs in a helical positively charged binding cleft
(Abbas and others 2013). Besides associating with 5¢ PPP-
RNA, IFIT1 has the ability to directly associate with capped
RNA that lacks a methylation mark at the ﬁrst ribose (2¢ON1
unmethylated RNA) (Habjan and others 2013; Kumar and
190 GEBHARDT, LAUDENBACH, AND PICHLMAIR
D
o
w
n
lo
ad
ed
 b
y
 M
P
I 
- 
(O
L
D
) 
- 
M
ax
-P
la
n
ck
-G
es
el
ls
ch
af
t 
fr
o
m
 w
w
w
.l
ie
b
er
tp
u
b
.c
o
m
 a
t 
0
5
/3
1
/1
8
. 
F
o
r 
p
er
so
n
al
 u
se
 o
n
ly
. 
2. Nucleic Acid Immunity
31
others 2014). Viruses that fail to methylate the 2¢O position of
the ﬁrst ribose are attenuated in wild-type mice but are highly
pathogenic in IFIT-deﬁcient animals (Dafﬁs and others 2010;
Leung and Amarasinghe 2016). It is yet not entirely clear how
IFIT1 and -5 impair virus growth but the high amounts of
IFIT proteins expressed after IFN treatment suggests
stoichiometric interference with viral nucleic acids rather
than enzymatic activity of IFIT proteins (Habjan and others
2013; Kumar and others 2014). Pathogenic alphaviruses that
generate high afﬁnity dsRNA secondary structures on the 5¢-
end of their genome evade surveillance by IFIT proteins
(Hyde and others 2014). IFIT1 appears to show surprisingly
little efﬁciency against negative strand RNA viruses in vivo
despite that these viruses are known to generate 5¢ PPP-RNA
(Pinto and others 2015). Potential explanations may be eva-
sion strategies of these viruses, including replication in the
nucleus that is not surveyed by IFIT proteins (eg, for IAV) or
generation of secondary structures of the RNA 5¢-end as has
been shown for alphaviruses (Pinto and others 2015). IFITs
have also been proposed to be (Berchtold and others 2008;
Zhang and others 2013; Imaizumi and others 2016) or not to
be (Pichlmair and others 2011; Habjan and others 2013) in-
volved in regulation of antiviral gene expression. Thus, the
activity of IFIT proteins is not yet fully understood and
highlights the importance of functional studies that will give
further mechanistic insights.
While the induction of type I IFNs and cellular restric-
tion mechanisms are partially well understood, relatively
little is known about the cellular machinery that speciﬁ-
cally degrades vRNA. A prominent machinery responsible
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Effector Protein
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PPP-RNA
PPP
RIG-I
IRFs
IFIT1 IFIT5
Viral
Translation
DDX60 MTR4 | ZCCHC7
Exosome
RNA
Degradation
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? ?
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dsRNA
DDX60 MTR4 | ZCCHC7
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MDA5
IRFs
DDX3
Virus
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Degradation
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B
FIG. 3. Cellular sensor and ef-
fector proteins binding viral nu-
cleic acids. (A) Sensing of dsRNAs
by MDA5 results in expression
of IFN-a/b. These in turn upregu-
late additional sensors including
dsRNA-dependent PKR and
OAS1. Binding of PKR to dsRNA
phosphorylates the translation ini-
tiation factor eIF2-leading to an
inhibition of translation and an
induction of apoptosis. OAS1
synthesizes 2¢-5¢-oligoadenylates
activating RNASEL. Activation of
RNASEL results in RNA degra-
dation and apoptosis. DDX60,
ATP-dependent RNA helicase
SKIV2L2 (MTR4) and ZCCHC7
promote vRNA degradation via
the exosome complex upon virus
infection. DDX3 activates IFN
signaling and restricts virus repli-
cation. (B) Engagement of 5¢-
triphosphorylated-RNA by RIG-I
leads to the expression of type I
IFNs, thereby inducing the ex-
pression of the effector proteins
IFIT1 and IFIT5. Sensing of PPP-
RNA by IFIT1 and IFIT5 leads to
decreased viral translation and re-
striction of virus, respectively.
vRNA can be recognized and de-
graded by the exosome cofactors
DDX60, MTR4, and ZCCHC7.
DDX3, DEAD box protein 3;
DDX60, DEAD box protein 60;
eIF2, eukaryotic initiation factor 2;
IFIT, interferon-induced protein
with tetratricopeptide repeats; IFN,
interferon; IRFs, interferon reg-
ulatory factors; MTR4, ATP-
dependent RNA helicase SKIV2L2;
OAS1, 2¢-5¢-oligoadenylate synthe-
tase 1; PKR, double-stranded RNA-
dependent protein Protein Kinase R;
PPP-RNA, triphosphorylated RNA;
vRNA, viral RNA; ZCCHC7, Zinc
ﬁnger CCHC domain-containing
protein 7.
SELF AND NON-SELF RIBONUCLEIC ACIDS DISCRIMINATION 191
D
o
w
n
lo
ad
ed
 b
y
 M
P
I 
- 
(O
L
D
) 
- 
M
ax
-P
la
n
ck
-G
es
el
ls
ch
af
t 
fr
o
m
 w
w
w
.l
ie
b
er
tp
u
b
.c
o
m
 a
t 
0
5
/3
1
/1
8
. 
F
o
r 
p
er
so
n
al
 u
se
 o
n
ly
. 
2.3. Discrimination of self and non-self RNA
32
for RNA degradation is the exosome, a large molecular
complex with 3¢-5¢ exonuclease activity. However, this
complex requires accessory factors that mark RNA for
degradation. Recently, the Ski2-like protein DDX60 was
identiﬁed as cellular protein that promotes degradation of
vRNA of diverse viruses through the exosome (Oshiumi
and others 2015). Furthermore, DDX60 has been proposed
to support RIG-I and MDA5-dependent induction of type I
IFNs (Oshiumi and others 2015). However, the role of
DDX60 appears complex since other laboratories found
little effect of DDX60 in antiviral immunity (Goubau and
others 2015; Grunvogel and others 2015). More recently,
superkiller viralicidic activity 2-like 2 (SKIV2L2; also
called Mtr4) and Zinc ﬁnger CCHC domain-containing
protein 7 (ZCCHC7), components of the Trf4/Air2/Mtr4p
polyadenylation (TRAMP) complex, were identiﬁed to
colocalize with vRNA and the exosome in the cytoplasm of
infected cells (Molleston and others 2016) and the helicase
SKI2W (SKIV2L) RNA exosome has been shown to pre-
vent autoimmunity by regulating the abundance of RIG-I
ligands (Eckard and others 2014) suggesting that vRNAs
are speciﬁcally targeted for decay.
Concluding Remarks
The knowledge on virus sensing and restriction has dra-
matically increased in recent years. It became evident that the
innate immune system particularly senses RNA that is in-
sufﬁciently processed and therefore lacks motifs commonly
found on cellular RNA. The ability of cytoplasmic PRRs to
sense such missing-self motifs allows them to be broadly
active and to detect nucleic acids generated by viruses and
other pathogens such as bacteria. In case of failure to properly
process cellular RNA this ability also bears the risk of in-
ducing unwanted immune responses that can lead to auto-
immune disorders. Besides nucleic acid sensors, a set of
cellular proteins exists that directly restricts viruses or leads
to changes in cellular machineries ranging from translational
control to cell death. More mechanistic insights into the
regulation and function of nucleic acid binding proteins are
important to understand antiviral immunity and to exploit this
knowledge for therapeutic interventions.
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2.4 Restriction Factors
Sensing of nucleic acids by the aforementioned PRRs results in the activation of
signaling cascades, the expression of cytokines and immune responses. A subgroup of
host restriction factors is as well capable of detecting foreign nucleic acids. However,
this aﬃnity results in the direct restriction of the nucleic acid function without the
activation of an immune response. Restriction factors are constitutively expressed in
nearly all cell types thereby granting to act very early in the defense against incoming
viruses. In infected cells, their expression is often increased by cytokine signaling.
Restriction factors mostly target conserved viral structures allowing them to target a
broad spectrum of viral families. In order to evade restriction factors, viruses evolved an
arsenal of counter mechanisms, thereby putting evolutionary pressure on those proteins
causing them to evolve rapidly.
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Figure 10: Overview of restriction factors important for antiviral or anti-
inflammatory immunity including IFIT1 and PKR leading to an inhibition of translation,
ADAR1 that destabilizes RNA, OAS inducing cleavage of nucleic acids and APOBEC proteins.
In the following section the function of RNA-binding viral restriction factors is described.
These factors do either activate other proteins with eﬀector functions (PKR and OAS),
function as restriction factor on their own (IFIT1 and Schlafen family member 11) or
modify the RNA (APOBEC proteins and ADAR).
One of the ﬁrst restriction factors to be identiﬁed was PKR85. This interferon-induced
protein is activated by the binding of double-stranded RNA. Upon binding, PKR
dimerizes and phosphorylates the eukaryotic translation initiation factor eIF2α. This
inhibits cellular ribosomal translation of mRNAs, thereby restricting the synthesis of
viral proteins (Figure 10). Viruses evolved mechanisms to counteract PKR activity,
highlighting its importance in antiviral defense. Mechanistically, PKR deactivation can
be achieved through degradation of PKR (NSs protein of RVFV), blocking of PKR
dimerization (NS5A of Hepatitis C Virus), sequestration of double-stranded RNA (NS1
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of Inﬂuenza A Virus, E3L of Vaccinia Virus) and dephosphorylation of eIF2α (γ34.5 of
Herpes Simplex Virus 1)86.
The OAS system is another highly active, versatile antiviral machinery87;88. Binding of
long double-stranded RNA leads to the activation of OAS resulting in the generation
of 2’-5’-linked oligoadenylates (2’5’-OA) that serve as second messengers and activate
RNase L. Binding of 2’5’-OA to RNase L induces dimerization and activation of its
endonuclease activity to cleave all RNA species in the cell causing a restriction of virus
growth (Figure 10)89.
Proteins that directly act as restriction factor include the IFIT proteins were known to
be induced by type I interferon and linked to regulation of translation. However, only
recently it could be shown that IFIT1 and IFIT5 are able to detect 5’-triphosphorylated
RNA, thereby inhibiting the replication of single-stranded RNA viruses90;91. At the
current stage it is not clear how virus inhibition is mechanistically executed but the high
number of IFIT molecules in interferon treated cells suggest a stoichiometric function.
Besides binding PPP-RNA, IFIT1 is able to associate with viral capped RNAs lacking
a methylation mark at the 2’-O-position of the ﬁrst ribose. Such RNAs are commonly
present in lower eukaryotes and certain viruses that lack 2’-O methyltransferases. IFIT1
binding leads to sequestration of 2’-O unmethylated RNA and prevents binding of the
RNA to eukaryotic translation initiation factors. This leads to a highly selective block
of translation while other cellular mRNAs can be properly translated (Figure 10)92.
As for other restriction factors, viruses evolved counter mechanisms to escape IFIT1
activities. These mechanisms include generation of RNA that is methylated on the 2’-O
position by acquiring 2’-O methyltransferases93. Moreover, alphaviruses which lack
2’-O methylation are still able to circumvent restriction by mouse Iﬁt1 by encoding for
structural elements adjacent to the cap structure94.
Schlafen family member 11 (SLFN11) acts more speciﬁcally in restricting retrovirus
growth. It directly binds tRNAs thereby limiting speciﬁcally the availability of tRNAs
for the production of proteins for HIV by exploiting a viral codon bias towards adenosines
at the third position.95.
Furthermore, the modiﬁcation of nucleic acids can restrict virus growth. APOBEC3G
and other APOBEC family members exert cytidine deaminase activity to mediate
deoxycytidine to deoxyuridine mutations in the genome of a variety of viruses, including
Human Immunodeﬁciency Virus (HIV). These hypermutations in the viral genome
result in erroneous replication and consequently in non-infectious virions (Figure 10)96.
The HIV protein viral infectivity factor (Vif) however counteracts this functions by
ubiquitinating APOBEC3G leading to proteasomal degradation97.
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Adenosine deaminase acting on RNA 1 (ADAR1) associated with double-stranded RNAs
and functions as a deaminase converting adenosines to inosines in certain RNAs. Thereby
the complementary base pairing between A:U is impaired making the RNA unstable
(Figure 10). This mechanism prevents the formation of stimulatory double-stranded
RNA molecules that could potentially activate MDA5 leading to an erroneous immune
response. Therefore ADAR1 acts rather as a restriction factor of potentially stimulatory
endogenous nucleic acids than as a restriction factor against viral nucleic acids98.
2.5 Nucleases and Nucleic Acid Metabolism
Some cellular nucleases act as important factors restricting the stimulatory potential of
nucleic acids, including nucleic acids of endogenous origin. Amongst those proteins is
the endolysosomal DNase II, which plays an important role in the degradation of nucleic
acids that accumulate during apoptotic cell death. Its importance was highlighted by
the ﬁnding that mice lacking DNase II develop a chronic activation of type I interferon
signaling via the cGAS-STING pathway99 (Figure 11). Recent systematic screening
approaches identiﬁed deﬁciency in DNAse II as causative reason for an interferonopathy
in humans100.
A surplus of endogenous nucleic acids, resulting from dead cells and chromatin debris
in the extracellular space, can trigger immune responses by TLRs upon endocytosis.
The extracellular DNase I represents an important nuclease prohibiting pathogenic
accumulation of DNA in the extracellular space that would result in unwanted immune
responses (Figure 11)101.
The 3’-repair exonuclease (TREX1) is critical for the removal of endogenous DNA
in the cytoplasm of cells. TREX1 is suggested to remove single-stranded DNA from
endogenous retroelements and reverse-transcribed DNA102. Loss of function mutations
in the human TREX1 gene lead to increased levels of DNA species in the cytosol that can
be recognized by the cGAS-STING axis and ultimately cause a severe interferonopathy
named Aicardi-Goutie`res syndrome (AGS) (Figure 11)103.
The RNases H are endonuclease complexes, which are involved in DNA repair cleaving
the RNA moiety of RNA:DNA hybrids. Characterization of the two RNase H complexes
RNase H1 and RNase H2 revealed that mutations in the three subunits of speciﬁcall
RNase H2 (RNase H2A, RNase H2B and RNase H2C) can cause AGS104. RNA:DNA
hybrids have been shown to function in vitro as endogenous stimulatory substrates
for the cGAS-STING pathway105 and TLR9106 (Figure 11). In 2009, SAMHD1 could
be added to the list of genes aﬀected in patients suﬀering from AGS, the molecular
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Figure 11: Cellular nucleases important for nucleic acid immunity. The cellular
nucleases TREX1, RNase H2, SAMHD1, DNase I and DNase II play important roles in removing
potential endogenous stimulatory nucleic acids.
mechanism however remained enigmatic (Figure 11).
Originally described as type I interferon induced protein with triphosphohydrolase
activity, SAMHD1 was shown to act as a restriction factor for HIV-1 infections107.
Besides its triphosphohydrolase activity it was proposed to function as a ribonuclease108.
More recently, it was shown that interferon production in SAMHD1 deﬁcient cells
requires as well the cGAS-STING pathway109 the exact substrate, however, is still
unknown.
2.6 Immunopathology triggered by deregulation of Nu-
cleic Acid Immunity
Type I interferonopathies can be characterized as a genetically heterogeneous group
of autoinﬂammatory disorders due to an erroneous and chronic activation of the an-
tiviral type I interferon response. The current knowledge of the pathology underlying
autoinﬂammation was inﬂuenced by progress in our understanding of the innate immune
system, foremost the identiﬁcation of pattern-recognition receptors and the activation
of signaling pathways culminating in the expression of type I interferons. Moreover, the
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discovery of mutations in genes coding for the nucleases Trex1, Dnase I, DNase II or
RNase H2 in patients with AGS further pointed to a close connection between innate
immune activation and autoimmunity. The recognition of self nucleic acids by pattern
recognition receptors is therefore key in the pathogenesis of type I interferonopathies
since an inappropriate activation of the type I interferon axis leads to severe eﬀects for
the host by the development of autoinﬂammation.
The term autoinﬂammation was shaped when the molecular mechanisms of tumor
necrosis factor receptor-associated periodic fever syndrome were elucidated. A self-
directed inﬂammation was thereby noticed rather than an involvement of the adaptive
immune system including B- or T-cells.
A uniting phenotype of type I interferonopathies is the anomalous upregulation of type I
interferons. With our current knowledge, four sources of an abnormal interferon response
can be classiﬁed. (1) Nucleic acids bearing atypical modiﬁcations or the accumulation
of endogenous nucleic acids, (2) increased sensitivity or activation of pattern recognition
receptors independent of a ligand, (3) defects in the regulation of nucleic acid-dependent
interferon signaling pathways, (4) defects in the nucleic acid independent modulation of
interferon responses.
Currently, more than twelve genetic disorders are known that can be categorized as a type
I interferonopathy. Amongst those is the prototypic Aicardi-Goutie`res syndrome (AGS).
It is a rare, early onset childhood disorder and characterized as a leukoencephalopathy
with elevated interferon levels in the cerebrospinal ﬂuid, cerebral calciﬁcations, cerebral
atrophy, seizures and intermittent fever110. An important biomarker of AGS is the
interferon signature. Whereas interferon levels in the cerebrospinal ﬂuid seem to decline
over time, the upregulation of interferon-stimulated genes (ISGs) in the blood is a
consistent marker111. AGS is a heterogeneous disease and results from mutations in
any of at least seven genes including TREX1, ADAR, RNase H2A, RNase H2B, RNase
H2C, SAMHD1 and MDA5 (Figure 12). Some AGS patients show indications which
are noticed as well in patients with Systemic Lupus Erythematosus (SLE).
SLE is a chronic, autoimmune disease where patients show signs of dermatitis, arthritis,
fever, rash and swollen lymph nodes112. Unlike AGS or other interferonopathies, SLE is a
multifactorial disease where genetic and environmental factors play a role. The molecular
pathology of SLE involves an immune response by the generation of autoantibodies
(mostly anti-nuclear antibodies targeting DNA) that induce inﬂammation. Like AGS
patients, SLE patients as well show signs of an interferon signature in peripheral blood113.
Mutations in the genes of TREX1, RNase H2A, RNase H2B and RNase H2C provide
a higher risk for SLE114. Moreover, mutations in the already previously introduced
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Figure 12: Type I interferonopathies triggered by genetic defects in nucleic acid
immunity. Mutations in genes of cellular nucleases like TREX1, SAMHD1, RNase H2, DNase
I or DNase II are causative for the development of a pathogenic type I interferon response and
the development of autoinﬂammatory diseases.
extracellular nuclease DNase I have been identiﬁed in SLE patients (Figure 12)115.
Although endogenous extracellular nucleic acids can lead to an aberrant interferon
response, cytoplasmic self-nucleic acids are as harmful since most nucleic acid sensing
receptors reside within the cytoplasmic cellular compartment. Defective degradation
of endogenous DNA species like single-stranded DNA metabolites, which continuously
emanate during DNA damage repair, single-stranded DNA polynucleotides from pro-
cessing of abnormal replication intermediates, or from endogenous retroelements can
activate the cGAS-STING axis. This can be prevented by the excellent waste handling
of the cellular nucleases like TREX1 or RNaseH2.
However not only endogenous DNA could potentially activate cytoplasmic DNA sensors,
RNA sensors like RIG-I or MDA5 could as well sense endogenous RNA species. Interest-
ingly, only recently superkiller viralicidic activity 2-like (SKIV2L), a component of the
exosome complex, was discovered to play an important role in the degradation of aber-
rant RNAs116. These abnormal RNAs containing 2’3’-cyclic phosphates originate from
the regulated IRE-1-dependent RNA decay (RIDD) involved in the unfolded protein
response as previously described (Figure 12)51. Moreover, genetic studies identiﬁed that
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polymorphisms in the gene of SKIV2L lead to a potential risk of developing SLE117.
Together, the mechanisms described above underline the outstanding importance of
proper cellular nucleic acid waste handling, however it still remains unclear how for
instance endogenous stimulatory triphosphorylated RNAs like 5S rRNA, or ncRNAs
are rendered harmless.
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3. Viral RNA Degradation
Virus infection triggers the activation of PRRs that recognize incoming viral nucleic
acids, virus replication intermediates or replication by-products. This sensing leads to
the massive induction of cytokines, chemokines and the expression of antiviral genes
ultimately leading to inﬂammation. In case of a successful defense from virus infections,
an important cellular task is to remove the immune stimulatory viral nucleic acids in
order to return to a homeostatic situation and to contain the eﬀects originating from
inﬂammation. As mentioned above, several diseases are linked to the incapability of
cells to degrade stimulatory endogenous nucleic acids leading to the development of
autoinﬂammatory diseases like the interferonopathies AGS and SLE. The genes included
in these processes include nucleases like DNase I, DNase II or TREX1 that are able to
degrade endogenous DNA or RNase H2 involved in the removal of RNA:DNA hybrids.
However, surprisingly little is known about the ability of cells to degrade viral or im-
munostimulatory nucleic acids. Yet, an interesting computational approach highlighted
the importance of viral RNA degradation in Inﬂuenza A Virus (IAV) infected cells.
Generating a mathematical model and calibrating it with experimental data covering all
steps of the viral life cycle revealed that RNA degradation is an important parameter
in the successful replication of IAV. By calculating the model parameters for viral RNA
decay and diﬀusion time, it could be shown that the diﬀusion distance from the site
of membrane fusion with the endosomal membrane and translocation to the nucleus
impacts RNA degradation rates: the shorter the distance of diﬀusion to the nucleus, the
lower the probability of viral RNA degradation. This computational ﬁndings could also
be substantiated by experimental data showing viral RNA degradation when nuclear
import was blocked by importazole118.
As previously described, viral nucleic acids diﬀer from cellular RNAs in several ways.
This includes structural diﬀerences, double-strandedness, the lack of poly(A) tails, or
the presence of 5’-PPP structures. One could hypothesize that the cell uses chemical or
structural modiﬁcations that mark viral RNAs to speciﬁcally degrade such nucleic acids.
However, surprisingly little is known about degradation pathways that are targeting
viral nucleic acids. What is the relative contribution of the cellular known degradation
mechanisms to decay viral RNA? How does perturbation of these RNA degradation
mechanisms modulate virus growth in vitro and in vivo? Which proteins are mediating
speciﬁcity for viral RNA degradation?
One of the major cellular RNA turnover pathways is the 5’-3’ degradation pathway
involving deadenylation, decapping and subsequent RNA degradation by the exonuclease
XRN1. Only recently, viral nucleic acids were shown to be sensitive to this decay route.
The Lemon group showed that synthetic Hepatitis C Virus (HCV) RNA harboring a
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5’-triphosphate end is rapidly degraded with a half-life of around 1.5h. In contrast, the
median half-life of cellular mRNAs is 9 hours and therefore much more stable119. This
suggests a targeted degradation of viral nucleic acids compared to host RNA. Knocking
down the exonuclease XRN1 led to a stabilization of the PPP-RNA by increasing the
half-life to more than 3h (Figure 13)120. Notably, although XRN1 may be able to
degrade the RNA body, degradation can only be initiated after the removal of the
5’-PPP group. This suggests involvement of a cellular enzyme that removes two of the
three phosphates to leave a monophosphate on the RNA, which subsequently can be
degraded by XRN1121. The activity of such a pyrophosphatase may be analogous to
the activity of decapping enzymes that remove the 5’-cap structure in order to allow
XRN1-dependnet cleavage of RNA.
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Figure 13: Viral RNA Degradation Pathways involve factors of all known cellular RNA
degradation mechanisms including XRN1 from the 5’-3’ decay pathway, factors of the NMD
pathway and the exosome complex.
NMD is another cellular process responsible for rapid degradation of aberrant cellular
mRNA46;122;123;124. NMD is operative on translating non-functional RNAs. Cellular
mRNAs with long 3’UTRs or premature stop codons can be detected by proteins of the
NMD pathway125;126 and are subsequently eliminated by the exosome complex. Since
viral nucleic acids possess features of aberrant RNAs there is increasing evidence that
they are recognized as targets of the cellular RNA degradation machinery. A genome-
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wide siRNA screen that tested for host factors restricting Semliki Forest Virus (SFV)
growth, identiﬁed the NMD components SMG5, SMG7 and UPF1 as targets and their
depletion led to an increase in virus replication during the early phase of infection127.
This indicates that viruses with single-stranded, positive-sense RNA genomes can be
detected and degraded by NMD (Figure 13). Due to the fact that NMD is translation-
dependent, the genomes of DNA viruses, retroviruses and negative-sense RNA viruses
can most likely not be targeted by NMD.
Besides being targeted for degradation by NMD or the 5’-3’ decay pathway, the 3’-5’
decay pathway including the exosome complex was implicated in degradation of viral
RNA. Multiple RNA binding proteins linked to antiviral immunity were shown to
interact with the exosome complex implying that RNA degradation is accomplished
through those complexes. Amongst factors that associate with viral RNA and the
exosome is DDX17, which restricts Rift Valley Fever Virus (RVFV) growth and is
directly binding the exosome (Figure 13). Though, the mechanism of inﬂuencing RVFV
growth is not clear yet128;129.
Recent work by the Sara Cherry group, revealed that the TRAMP complex compo-
nents MTR4 and AIR1 (Zcchc7) are antiviral against several RNA viruses including
RVFV, Vesicular Stomatitis Virus (VSV) and Sindbis Virus (SINV). Interestingly, these
components are generally part of the strictly nuclear TRAMP complex. Notably, in
infected cells MTR4 and AIR1 translocate to the cytoplasm where they form a complex
with the cytoplasmic exosome and viral RNAs (Figure 13). The RNA of RVFV was
found to be stabilized in the absence of AIR1, suggesting targeted degradation of viral
transcripts by this newly identiﬁed cytoplasmic TRAMP complex. Attaching GFP to
the 3’ UTR of RVFV and subsequently infecting the cells was suﬃcient to target the
GFP-tagged transcript for degradation, implying that infectious conditions trigger a
selective degradation by the exosome complex130.
A further study showed that the cytidine deaminase (AID), a member of the APOBEC
family, interacts with a viral RNP complex of Hepatitis B Virus (HBV) consisting
of the viral P protein and the epsilon RNA sequence essential for HBV replication.
Besides binding to the viral RNP complex, AID was as well shown to recruit the RNA
exosome (Figure 14). Moreover HBV-levels are reduced in an AID-dependent manner
indicating that interaction of AID with the viral RNP complex and the RNA exosome
leads to RNA degradation by the exosome131. HBV is able to evade the induction
of the interferon system. However, the virus can still be cleared in most patients to
a high extent, suggesting cellular restriction pathways that eﬃciently restrict HBV
replication in an interferon-independent manner. In a functional screen for helicases
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that could potentially modulate HBV replication, the SKIV2L helicase, member of the
cytoplasmic Ski complex, was identiﬁed. Furthermore, interaction of SKIV2L with the
HBV X-RNA was shown to be indispensable for degradation of the X-mRNA. This
degradation seems to involve the protein HBS1, which is a factor also involved in the
cellular RNA surveillance pathways (Figure 14)132.
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Figure 14: Degradation of HBV nucleic acids. Diﬀerent HBV nucleic acids (X-RNA, and
-RNA are recognized by RNA binding proteins leading to degradation by the exosome complex.
In the nucleus APOBEC proteins deaminate the covalently closed circular DNA (cccDNA) which
leads to degradation by nuclear nucleases.
Additionally, the Protzer laboratory showed that stimulation of the lymphotoxin beta
receptor (LTβR) upon HBV infection leads to the expression of proteins of the APOBEC
family. APOBEC3A and APOBEC3B translocate to the nucleus in HBV infected cells
and lead to cytidine deamination of the nuclear covalently closed circular DNA (cccDNA),
a highly stable state of the genomic HBV DNA. Deamination of the cccDNA led to
degradation in cell culture (Figure 14)133. However it is yet unclear how the modiﬁed
RNA gets degraded in the nucleus. In patients with chronic HBV infection no impact
on cccDNA turnover could be observed despite activation of LTβR gets134.
The interferon system is the main executor of antiviral responses and a number of
interferon stimulated genes bear nuclease activity. Amongst those is the interferon-
induced RNase L, which cleaves a broad range of RNAs without apparent discrimination
between viral and cellular nucleic acids (Figure 15). However some reports point towards
a partial selectivity of viral nucleic acids. First, cellular RNAs especially tRNAs and
rRNAs are modiﬁed heavily on internal nucleotides thereby representing only suboptimal
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Figure 15: Interferon-induced nucleic acid degradation pathways. The interferon-
induced zinc-ﬁnger antiviral protein (ZAP) is able to recruit the RNA decay machinery upon viral
RNA binding. RNaseL stimulated by the interferon-induced generation of 2’5’-oligoandenylates
is activated to cleave various nucleic acids
substrates for RNase L135. Second, RNase L strongly favors UU or UA sequences as
cleavage sites, which are not found frequently in mammalian codons136. Another
example for an interferon induced nuclease is zinc-ﬁnger antiviral protein (ZAP) that
has the ability to speciﬁcally target RNAs bearing ZAP response elements though its zinc
ﬁnger domain. ZAP response elements commonly found in many viruses137;138. Upon
RNA binding, ZAP recruits the whole RNA decay machinery including the exosome
complex, the deadenylase PARN and the decapping enzymes DCP1 and DCP2 (Figure
15)139. The mechanism, however, is still not entirely explored and it is not clear if
ZAP-dependent restriction of virus growth is due to degradation of the viral RNAs or
any other potential mechanism.
In sum, several lines of evidence suggest involvement of the exosome complex as well as
XRN1 – dependent degradation in the turnover of viral nucleic acids. However, currently
it is enigmatic how speciﬁcity is conferred to viral RNA in order to allow speciﬁcity. To
date, no mechanism was identiﬁed that would speciﬁcally target viral nucleic acids for
degradation.
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4. The Mammalian Phosphatome
The phosphatome refers to the entire set of proteins with phosphatase activity encoded
in the genome. Phosphatases are enzymes capable of removing a phosphate moiety from
various biomolecules and thereby fulﬁl important biological functions in metabolism,
signaling and nucleic acid processing. The biochemistry of phosphate removal represents
a typical hydrolysis reaction with a water molecule as attacking group and results in
the generation of a phosphate ion and a molecule with a free hydroxyl (OH) group.
The attack of the water molecule can be catalyzed by divalent metal ions or histidine-,
cysteine-, or serine-residues. The classiﬁcation of phosphatases is nearly as diverse as
their molecular functions and includes categorization into either alkaline phosphatases
or acid phosphatases, classiﬁcation according to their active-site catalytic group (met-
alphosphatases, serinephosphatases, histidinphosphatases or cysteinphosphatases140) or
according to their protein structural fold141. Typically, phosphatases do not recognize
their substrate within the active site but rather bind multiple residues with weak binding
aﬃnity. However the cumulative eﬀect of multiple weak interactions provides an increase
in binding speciﬁcity to the substrate142.
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Figure 16: The human phos-
phoproteome subdivided in 19
protein structural folds. Depicted in
blue are protein-phosphatases and
in grey non-protein phosphatases
Only recently, Chen et al. classiﬁed human phosphatases141. By including input from
databases, protein sequence similarity searches and literature it was possible to create
a phosphatome of 264 phosphatases. Based on structural databases, the human phos-
phatome can be subdivided into proteins with 19 diﬀerent protein folds (Figure 16).The
largest group is comprised of the human protein phosphatases, which dephosphorylate
post-translationally modiﬁed proteins on tyrosine or serine/threonine residues. The
group of protein phosphatases includes alkaline phosphatases (AP), the cysteine-based
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phosphatases (CC1, CC2, CC3), haloacid dehydrogenases (HAD), metal-dependent
protein phosphatases (PPM), protein histidine phosphatases (PHP), Phosphoprotein
phosphatase-like phosphatases (PPPL), histidine phosphatases (HP), and a phosphatase
of the regulator of transcription fold (RTR1). The group of non-protein phosphatases is
more diverse and less well studied. However, they play important roles in metabolism
where the addition or removal of phosphate groups changes the energy of metabolic
intermediates, in the processing of nucleic acids, or in the regulatory role of phospho-
inositide lipids.
Nudix Hydrolases
Non-protein phosphatases with a Nudix fold comprise a protein superfamily of metal-
dependent phosphatases. These Nudix hydrolases are conserved in 250 species including
bacteria, archea and eukaryotes143. Proteins of the Nudix superfamily catalyze the
hydrolysis of nucleoside diphosphates linked to other moieties (X) and contain the
conserved sequence motif GX5EX5[UA]XREX2EEXGU where U is a bulky amino acid
and X can be any amino acid144.
Capped mRNAs
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Nucleotides
Oxidized 
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Capped snoRNAs
Diphosphoinositol
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Hydrolases
Figure 17: Substrates of Nudix Hydrolases. Substrates of human Nudix hydrolases are
very diverse and range from single nucleotides to nucleotide sugars, capped RNA and nucleotide
polyphosphates.
This so called Nudix box forms a structural motif of a loop - α-helix - loop structure,
which harbors the catalytic residues. This motif is part of an α/β/α sandwich making
up the Nudix fold145. The substrates that are dephosphorylated by Nudix hydrolases
are very diverse ranging from nucleoside triphosphates, polyphosphates, and nucleotide-
sugars to capped mRNAs (Figure 17). Consequently, they are known to play very diverse
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roles in cellular metabolism and cell homeostasis, as well as mRNA processing146;147.
The mechanism of Nudix hydrolases resembles that of other metal-dependent phos-
phatases with a nucleophilic attack of a water molecule on the γ-phosphate of the
substrate and formation of a trigonal bypyramidal intermediate148. The double bond is
then reformed thereby displacing a monophosphorylated moiety as leaving group (Figure
18). The attacking water ligand is properly aligned by the electrostatic interactions
with divalent cations, mostly Mn2+ or Mg2+ that as well enhance the nucleophilicity of
water. In addition, two conserved glutamate residues in the Nudix box are critical for
the hydrogen bonding of the water molecule and the coordination of the metal ions. In
some cases, a third Mg2+ ion stabilizes the negatively charged phosphate of the leaving
group (Figure 18). The substrate speciﬁcity is not provided by residues within the
active site but rather by motifs elsewhere in the structure.
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Figure 18: Mechanism of phosphate removal by Nudix hydrolases. Metal-dependent
hydrolysis reaction by nucleophilic attack of a water molecule and displacement of a monophos-
phorylated moiety.
The human genome encodes for 24 Nudix genes. Although the ﬁrst NUDIX member
was already deﬁned in 1954, the biological role of most of the Nudix hydrolases still
remains unknown146. Only recently, a comprehensive study proﬁled the family of Nudix
hydrolases in more detail in terms of structural similarities, mRNA expression levels and
by screening 52 diﬀerent substrates for their sensitivity to Nudix activity149. Although
this study expanded our knowledge on Nudix hydorlases, the molecular functions and
their cellular targets remain enigmatic.
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5. Aim of the Thesis
Aim of the Thesis
Viruses are the most abundant pathogens on earth and represent a major threat to
human health. In order to grow and spread, viruses are strongly dependent on their
genetic material. In comparison to the highly processed host nucleic acids, viral nucleic
acids miss several of those features. Therefore sensing of virus infections mostly involves
the recognition of viral nucleic acids. In the past years, remarkable progress has been
made in the understanding of how foreign nucleic acids are sensed by the cell. However,
only little is known about the pathways of cells to degrade speciﬁcally viral nucleic
acids.
The genome of RNA viruses is protected from degradation by a 5’-triphosphate group.
Similar to mRNA degradation in eukaryotes where mRNA decay needs to be initiated
by the removal of the protecting 5’-cap structure by DCP2, the viral RNA would
need to be prepared for degradation by 5’-exonucleases. Therefore, the aim of this
thesis was to identify a mechanism that could speciﬁcally target viral nucleic acids
for degradation. The curiosity was sparked by a publication of Deana et al., who
identiﬁed a bacterial pyrophosphatase of the Nudix hydrolase superfamily (RppH)
to be able to dephosphorylate triphosphorylated bacterial mRNA. Interestingly, the
eukaryotic decapping enzyme DCP2 belongs as well to the Nudix hydrolase superfamily.
Therefore, I ﬁrst set out to screen all mammalian Nudix hydrolases for having an
impact on virus growth. After selecting four, I found only one Nudix hydrolase, namely
NUDT2, to dephosphorylate triphosphorylated RNA. I could show that NUDT2 releases
two phosphate groups of a triphosphorylated RNA in a sequential manner, leaving
behind a monophosphorlyated RNA that could serve as a substrate for the cellular
5’-exonuclease XRN1. Thereby NUDT2 initiates a RNA degradation pathway speciﬁc
to viral triphosphorylated RNAs.
Additionally, discriminating self- from non-self nucleic acids is of upmost importance
for host cells to launch a proper immune response. The crystal structure of the viral
restriction factor interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)
revealed novel insights in the binding of capped viral RNA. In collaboration with
Bhushan Nagar I aimed at functionally validating that cap-RNA binding of speciﬁc
residues in the cap-binding pocket are important for IFIT1-mediated inhibition of virus
growth.
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PUBLICATION 1
NUDT2 initiates viral RNA degradation by removal of 5’-phosphates
Beatrice T. Laudenbach, Alexander Reim, Markus Moser, Arno Meiler, Janos Ludwig and
Andreas Pichlmair. NUDT2 initiates viral RNA degradation by removal of 5’-phosphates.
Submitted to Science (2018)
Viruses are dependent on their genetic material in order to spread. However, if this viral genetic
material is subjected to degradation by cellular nucleases is not explored yet. The genome
of many RNA viruses is protected by a 5’-triphosphate group which does not allow digestion
by 5’-3’ nucleases. Very similar, host messenger RNAs are protected as well by a chemical
structure, namely the 5’- cap. Prior to mRNA degradation, the cap structure needs to be
removed by decapping protein 2 (DCP2). The generated monophosphorylated RNA is thereby
rendered susceptible to degradation by cellular exonuclease 1 (XRN1). In my PhD work, I
discovered that NUDT2, very similar to DCP2, removes phosphates from RNA substrates
generating a monophosphorylated RNA that serves as substrate for XRN1. This represents a
novel mechanism to degrade speciﬁcally viral nucleic acids. Its importance is highlighted by the
increased virus-load in cells lacking the Nudt2 gene.
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Supplementary Figure 3
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Supplementary Figure 4
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Sequence Name siRNA target sequence 5’->3’  
Hs_NUDT1_3 CTCCTGCTTCAGAAGAAGAAA 
Hs_NUDT1_4 CCGGGTTTCATCTGGAATTAA 
Hs_NUDT1_5 CCGCGAGGTGGACACGGTCTA 
Hs_NUDT2_10 CAGGCATCAGATGGCATTCAT 
Hs_NUDT2_7 TGCCAGGGTCCTGCAGTTATA 
Hs_NUDT2_8 AGGATCCTTGTGGGCCTTCTA 
Hs_NUDT5_2 CAGGCTTGTCAAACTGTACTA 
Hs_NUDT5_3 TACATGGATCCTACTGGTAAA 
Hs_NUDT5_6 TTCCTACGCTCTAGCACTGAA 
Hs_NUDT6_5 CACGCAGAATCGGATTCATCA 
Hs_NUDT6_6 CTGGTTGTACAAGATCGAAAT 
Hs_NUDT6_7 GAGCTGTATTTGATGAAAGTA 
Hs_NUDT9_5 ATGGATAATCTTATGCTAGAA 
Hs_NUDT9_6 CACGCTGCAGATCCCATTATA 
Hs_NUDT9_3 AAGATTAGTGCCACACTGAAA 
Hs_NUDT12_6 AGCCGAGCTATTGCACATCAA 
Hs_NUDT12_7 ATGATTGGTTGCTTAGCTCTA 
Hs_NUDT12_5 AAGGTCGGATATTAAATAAGT 
Hs_NUDT13_6 CAGGGAACGGAAGCCGTTGAA 
Hs_NUDT13_5 CCACAACGTGTTGATTAACAA 
Hs_NUDT13_7 TAGCCCGGATCAAGTCACTTA 
Hs_NUDT14_1 CAGCGTGACCGTTCTCTTATT 
Hs_NUDT14_2 AAAGGCTTGCATAGCTCCAAA 
Hs_NUDT14_4 CTCCAGACAGACCATGTTCTA 
Hs_NUDT15_4 CAGCAGTACTCTTCTCACTAA 
Hs_NUDT15_6 CTCAAGAGCCTTTCAAGGGTA 
Hs_NUDT15_7 ATCTGGTGTGATATTGTAATA 
Hs_NUDT16_1 CTCCCTGTTTATATGCGTACA 
Hs_NUDT16_2 CAGGTCAACACTAATACCACT 
Hs_NUDT16_3 ATGTATGAAGGTGGTTCTCAA 
Hs_NUDT17_7 CCCAACCATGGCAGAGGACAA 
Hs_NUDT17_6 CCCGGATCCAACCAAACCCAA 
Hs_NUDT17_5 TACCATCACATTGTTCTGTAT 
Hs_NUDT18_1 CTGGGCCGAGATCACAGTGAT 
Hs_NUDT18_2 AAGCGAGGAGTCCAAAGCTCA 
Hs_NUDT18_3 ATCCTGCACCTGGTTGAACTA 
Hs_NUDT19_4 TACGAAGTGAGAAGACTTGCA 
Hs_NUDT19_3 CACGTTTATCCTAAGAACTCT 
Hs_NUDT19_2 CACCGGATAGTGACATACCAT 
Hs_DCP2_5 CCGGTGATTCATGTTTGTGAA 
Hs_DCP2_6 CTGCTTATAAATGTTATTGTA 
Hs_DCP2_1 CTGGGTTATCAGAGTAATGAA 
Hs_NUDT21_5 CTGCACATATTACAAAGCCTA 
Hs_NUDT21_1 ATCGTGATGAGAAACCTAATA 
Hs_NUDT21_3 CCAAGTGTAGCTGAGCAATTA 
Hs_NUDT22_4 AGGCGCCATCATCCTCTACAA 
Hs_NUDT22_1 CTGGGCCTTACTTCCTACCGA 
Hs_NUDT22_3 CCGAGACTTCCTGGGCACCAA 
Hs_DDX58_6 (RIG-I) AACGTTTACAACCAGAATTTA 
Hs_DDX58_10 (RIG-I) TTCTACAGATTTGCTCTACTA 
Hs_DDX58_11 (RIG-I) CTCCTCCTACCCGGCTTTAAA 
Scrambled (control) AAGGTAATTGCGCGTGCAACT 
 
Supplementary Table 1 
siRNA target sequences used in the siRNA screen
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Sequence 
Name 
Sequence 5’ -> 3’ 
dsRNA IVT4 TTGTAATACGACTCACTATAGGGACGCTGACCCAGAAGATCTACTAGAAATAGTAGATCTTCTGGGTCAGCGTCCC 
dsRNA IVT4_as GGGACGCTGACCCAGAAGATCTACTATTTCTAGTAGATCTTCTGGGTCAGCGTCCCTATAGTGAGTCGTATTACAA 
G0 AATTCCTGCAGTAATACGACTCACTATAGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
G0_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCTATAGTGAGTCGTATTACTGCAGGAATT 
G8 AATTCCTGCAGTAATACGACTCACTATAGGAACAACGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
G8_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCGTTGTTCCTATAGTGAGTCGTATTACTGCAGGAATT 
G4[GGAA] AATTCCTGCAGTAATACGACTCACTATAGGAAGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
G4[GGAA]_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCTTCCTATAGTGAGTCGTATTACTGCAGGAATT 
G4[GAAA] AATTCCTGCAGTAATACGACTCACTATAGAAAGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC  
G4[GAAA]_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCTTTCTATAGTGAGTCGTATTACTGCAGGAATT 
G4[GCAA] AATTCCTGCAGTAATACGACTCACTATAGCAAGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
G4[GCAA]_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCTTGCTATAGTGAGTCGTATTACTGCAGGAATT 
G4[GUAA] AATTCCTGCAGTAATACGACTCACTATAGTAAGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
G4[GUAA]_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCTTACTATAGTGAGTCGTATTACTGCAGGAATT 
A8 AATTCCTGCAGTAATACGACTCACTATTAGAACAACGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
A8_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCGTTGTTCTAATAGTGAGTCGTATTACTGCAGGAATT  
A4[AGAA] AATTCCTGCAGTAATACGACTCACTATTAGAAGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
A4[AGAA]_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCTTCTAATAGTGAGTCGTATTACTGCAGGAATT 
A1 AATTCCTGCAGTAATACGACTCACTATTAGGCGCCGCGGTAACGCGGCGCCACGCGGAAACGCGCC 
A1_as GGCGCGTTTCCGCGTGGCGCCGCGTTACCGCGGCGCCTAATAGTGAGTCGTATTACTGCAGGAATT 
 
Supplementary Table 2 
Nucleotide sequences used as templates in in vitro transcriptions
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Sequence Name Sequence 5’ -> 3’ 
hu_NUDT2_fw CACTGGACTCCTCCCAAAGG 
hu_NUDT2_rv TCCTCTTGGGTCTCCCTCAG 
hu_NUDT12_fw TTGGGCAAAACTTGTATCGAC 
hu_NUDT12_rv CTTCATCCTCCTATGCCAGC 
hu_NUDT14_fw AAGAGAACGGTCACGCTGTC 
hu_NUDT14_rv CCGCCTCACCCTACCTG 
hu_NUDT17_fw GACTGTCTTGCTAACCCGAAG 
hu_NUDT17_rv GGCAGGTGTAGTCCACTCTC 
VSV-N_fw ATCGGAATATTTGACCTTGTA 
VSV-N_rv ACTGTTCATTGATCATTTTGC 
ms_ActB_fw CTCTGGCTCCTAGCACCATGAAGA 
ms_ActB_rv GTAAAACGCAGCTCAGTAACAGTCCG 
SFV-nsp3_fw GCAAGAGGCAAACGAACAGA 
SFV-nsp3_rev GGGAAAAGATGAGCAAACCA 
HSV-DNA Polymerase I_fw AGCCTGTACCCCAGCATCAT 
HSV-DNA Polymerase I_rv TGGGCCTTCACGAAGAACA 
Fireﬂy Luc_fw CTCACTGAGACTACATCAGC 
Fireﬂy Luc_rv TCCAGATCCACAACCTTCGC 
hu_GAPDH_fw GATTCCACCCATGGCAAATTC 
hu_GAPDH_fw AGCATCGCCCCACTTGATT 
 
Supplementary Table 3 
qRT-PCR primers used in this study
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Sequence Name Sequence 5’ -> 3’ 
NUDT2_gRNA1 ATGAGCACCAAGCCTACCGC 
NUDT2_gRNA2 AATTGCATTGTTGTCCACTT 
NUDT2_gRNA3 TAACTAGGCCATGTGGAACC 
NUDT2_gRNA4 CATCAGATGGCATTCATCAC 
NUDT2_gRNA5 TCTCCTTGAACTGAGCCAAC 
NUDT2_gRNA6 CCATTATTGAGGGGTTCAAA 
XRN1_gRNA1 TTAAGAGAAGAAGTTCGATT 
XRN1_gRNA2 TAAAACGCCTCCCACGCTGC 
XRN1_gRNA3 GCTTGGATTAACAAGTCATG 
XRN1_gRNA4 TAATGCGAAACAACACCTCC 
XRN1_gRNA5 GTATCCCTGTCTCAGCGAAG 
XRN1_gRNA6 TTTCACCACTTCGCTGAGAC 
 
Supplementary Table 4
Nucleotide guide sequences cloned in pLentiCRISPRv2
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Structure of human IFIT1 with capped RNA reveals adaptable mRNA
binding and mechanisms for sensing N1 and N2 ribose 2-O methyla-
tions
Yazan M. Abbas, Beatrice Theres Laudenbach, Sau´l Mart´ınez-Montero, Regina Cencic,
Matthias Habjan, Andreas Pichlmair, Masad J. Damha, Jerry Pelletier, and Bhushan Nagar.
Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms
for sensing N1 and N2 ribose 2’-O methylations. Proc Natl Acad Sci U S A 114, E2106-E2115
(2017).
The collaborative manuscript ‘Structure of human IFIT1 with capped RNA reveals adaptable
mRNA binding and mechanisms for sensing N1 and N2 ribose 2-O methylations’ published in
the Proceedings of the National Academy of Sciences (PNAS) presents novel insights into the
binding of capped RNA by IFIT1. The crystal structure of IFIT1 with capped RNA revealed
that a central positively charged tunnel that sterically excludes RNAs that are methylated at the
2’-OH positions of the ribose of the ﬁrst and second nucleotides. This structural feature thereby
provides speciﬁcity for viral capped RNAs that do not show these speciﬁc methylation marks in
contrast to cellular RNAs. The sequestration of capped RNAs lacking 2’-OH methylation by
IFIT1 prohibits binding of eIF4E and thereby inhibits translation of these RNAs. I contributed
with functional validation of IFIT1 mutant cells infected with a human coronavirus mutant
lacking the 2’-OH methyltransferase. My ﬁndings highlighted the importance of RNA binding
to IFIT1 and consequential IFIT1-mediated inhibition on virus growth.
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IFIT1 (IFN-induced protein with tetratricopeptide repeats-1) is an
effector of the host innate immune antiviral response that prevents
propagation of virus infection by selectively inhibiting translation of
viral mRNA. It relies on its ability to compete with the translation
initiation factor eIF4F to specifically recognize foreign capped mRNAs,
while remaining inactive against host mRNAs marked by ribose 2′-O
methylation at the first cap-proximal nucleotide (N1). We report here
several crystal structures of RNA-bound human IFIT1, including a 1.6-Å
complex with capped RNA. IFIT1 forms a water-filled, positively
charged RNA-binding tunnel with a separate hydrophobic extension
that unexpectedly engages the cap in multiple conformations (syn
and anti) giving rise to a relatively plastic and nonspecific mode of
binding, in stark contrast to eIF4E. Cap-proximal nucleotides encircled
by the tunnel provide affinity to compete with eIF4F while allowing
IFIT1 to select against N1 methylated mRNA. Gel-shift binding assays
confirm that N1 methylation interferes with IFIT1 binding, but in an
RNA-dependent manner, whereas translation assays reveal that
N1 methylation alone is not sufficient to prevent mRNA recognition
at high IFIT1 concentrations. Structural and functional analysis show
that 2′-Omethylation at N2, another abundant mRNAmodification, is
also detrimental for RNA binding, thus revealing a potentially syner-
gistic role for it in self- versus nonself-mRNA discernment. Finally,
structure-guided mutational analysis confirms the importance of
RNA binding for IFIT1 restriction of a human coronavirus mutant
lacking viral N1 methylation. Our structural and biochemical analysis
sheds new light on the molecular basis for IFIT1 translational inhibi-
tion of capped viral RNA.
IFIT1 crystal structure | innate immunity | mRNA cap recognition |
self vs. nonself | 2′-O methylation
Infection by a virus relies on its ability to exploit the host’stranslational machinery to convert its genome into protein
products that can ultimately be used to assemble new viral par-
ticles. In eukaryotes, endogenous mRNA is protected by a highly
conserved 5′ cap structure consisting of an N7-methylguanosine
triphosphate (m7Gppp/Cap0) moiety. This is recognized by the
eukaryotic translation initiation factor 4E to promote cap-
dependent translation (eIF4E together with eIF4G and eIF4A
comprise eIF4F) (1). In higher eukaryotes, the mRNA cap is
further modified by ribose 2′-O methylation on the first and
sometimes second cap-proximal nucleotides (N1 and N2, where
N is any nucleotide) (Fig. S1A), resulting in Cap1- (m7GpppNmN)
or Cap2- (m7GpppNmNm) mRNA (2, 3). N1 methylation was
recently shown to serve as a molecular signature of “self,” which can
subvert mammalian antiviral responses (4, 5). As such, many viruses
also produce Cap1-mRNA, either through the action of host- or
virally encoded 2′-O methyltransferases (MTases) or through viral
“cap-snatching” enzymes (6, 7). Hence, Cap0-mRNAs (along with
other virus-derived RNAs) are marked as “nonself” and can trigger
responses, such as the type I IFN antiviral program (5, 8, 9), which
culminates in the induction of hundreds of IFN-stimulated genes
(ISGs) (10).
Among the most potently induced of the ISGs are the IFITs
(IFN-induced proteins with tetratricopeptide repeats), a family of
antiviral effectors whose expression can also be triggered down-
stream of IFN-independent signaling (11). IFITs are conserved
throughout vertebrate evolution, with humans and most mammals
encoding five paralogues—IFIT1, IFIT1B, IFIT2, IFIT3, and
IFIT5—although many also possess species-specific duplications
and deletions. For example, mice lack IFIT5 and were only re-
cently discovered to have also lost IFIT1 (12). Therefore, what is
currently known as mouse Ifit1 (54% sequence identity with hu-
man IFIT1) is actually an ortholog of human IFIT1B. In humans,
IFIT1B (67% sequence identity with human IFIT1) is not known
to be IFN-inducible (11), and recent data suggest that it may be
nonfunctional (12). IFITs are structurally related and are com-
posed of tandem copies of the tetratricopeptide repeat (TPR), a
helix–turn–helix motif. Structures of several IFITs have shown that
their TPRs coalesce into distinct superhelical subdomains that
form clamp-shaped structures (13–16).
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Recently, it was discovered that IFITs play a prominent role in
impeding viral replication by directly binding the 5′ end of viral RNA
(17). Thus, IFIT1 and IFIT1B can compete with eIF4F to selectively
bind and sequester viral Cap0-mRNA, resulting in its translational
inhibition (18–20). In this manner, mouse Ifit1 has been shown to
restrict a broad spectrum of wild-type and mutant viruses lacking
2′-O MTase activity, including alphaviruses, coronaviruses, flavi-
viruses, and vaccinia virus (4, 18, 21–25), whereas mutating viral
N1 methylation enhanced coronavirus and flavivirus sensitivity to
human IFIT1 (18, 23, 24, 26). In contrast, host cellular mRNA is
not targeted as it bears N1 2′-O methylation, which interferes with
IFIT1 and IFIT1B binding (18–20). That many cytoplasmic virus
families have adapted by acquiring 2′-O MTases to generate their
own Cap1-mRNA, thereby potentially escaping IFIT1/IFIT1B
restriction, underscores the importance of these proteins in this
process (7). Furthermore, alphaviruses, which display only Cap0-
mRNA, can still subvert mouse Ifit1 activity by encoding cap-
proximal structural elements (21, 22), which has also been
shown to interfere with RNA binding and enhance pathogenicity.
IFIT1, along with IFIT5, can also recognize uncapped viral
triphosphate (PPP)-RNA (another nonself marker of infection) to
potentially inhibit the replication of some negative-sense single-
stranded (ss) RNA viruses (13, 17). The crystal structure of human
IFIT5 bound to uncapped PPP-RNA revealed that the RNA sits
in a narrow, positively charged tunnel at the core of the protein,
with a network of electrostatic interactions specifically recognizing
the PPP moiety (13). Up to four nucleotides are also stably bound
within the tunnel in a sequence-nonspecific manner. The sequence
identity between IFIT5 and IFIT1 (55%) and a structure of the
N-terminal region of IFIT1 suggested that IFIT1 accommodates
capped RNA in a similar fashion. However, IFIT5 cannot bind
capped mRNA (13, 18, 19), and indeed protein residues at the
base of the tunnel would block any further progression beyond the
PPP moiety. Thus, how IFIT1-like proteins can accommodate
Cap0-mRNA remains unclear.
We report here several crystal structures of RNA-bound human
IFIT1. The structures reveal that the positively charged
RNA-binding tunnel of IFIT1 is distinct from that found in
IFIT5 and further extended to allow binding of both capped and
uncapped RNAs. Strikingly, mRNA binding and cap recognition by
IFIT1 appears to be adaptable and its mechanism is evolutionarily
divergent from eIF4E and other cap-binding proteins. The shape of
the tunnel in the vicinity of the 2′-hydroxyls of N1 and N2 sterically
occludes RNA methylated at these positions. A comprehensive
analysis of the interaction between human IFIT1 and differentially
methylated capped RNAs corroborates the structural findings, re-
vealing that either N1 or N2 methylation alone interferes with
IFIT1 binding, but in an RNA-dependent manner. Combining
N1 and N2 methylation resulted in an additive and potentially
synergistic effect in inhibiting IFIT1 activity, particularly toward
susceptible RNA sequences and at high IFIT1 concentrations.
Our structural and biochemical analysis therefore sheds light on
IFIT1 antiviral activity and reveals a previously uncharacterized
role for N2 ribose methylation and Cap2 structures as signatures
of self mRNA.
Results
RNA Binding and Inhibition of in Vitro Translation by Human IFIT1.
The interaction between IFIT1 and capped-RNA is well established,
but the precise structural determinants of the viral RNA important
for binding are as yet unclear. Thus, we began by carrying out EMSAs
between human IFIT1 and two 5′ capped sequences derived from
genomes of coronaviruses known to be restricted by human IFIT1 or
mouse Ifit1: human coronavirus strain 229E (HCoV) and murine
hepatitis virus strain A59 (MHV) (18). Human IFIT1 bound the
capped-RNAs with apparent affinities of ∼250 nM and <100 nM,
respectively (Fig. 1A). Binding strength decreased as the stability and
proximity of RNA secondary structure to the 5′-end increased (Fig.
1A and Fig. S1B), confirming the preference for ssRNA as previously
demonstrated for human IFIT1 and mouse Ifit1 (13, 21). As with
IFIT5, RNA binding is generally sequence-nonspecific and replacing
the first 3 nt of HCoV (sequence ACU) with GGG resulted in only a
modest enhancement of binding (Fig. 1A, Right). IFIT1 also binds
uncapped PPP-RNA, but this is inherently weaker and more sensitive
to the presence of predicted secondary structure at the 5′-end (Fig.
S1C). This finding is in contrast to IFIT5, which binds PPP-RNA but
cannot accommodate capped RNA, as shown by its crystal structure
and a variety of biochemical assays from several groups (13, 18, 19).
To understand the contribution of IFIT1 binding to capped
RNA in a more physiological context, we used an in vitro trans-
lation system to assess the effect on translation initiation. The
system consists of Krebs extracts programmed with a bicistronic
Cap0-mRNA reporter (27). The 5′-cistron expresses a Firefly lu-
ciferase (FF) reporter that is translated in a cap-dependent man-
ner, whereas the 3′-cistron expresses a Renilla luciferase (Ren)
reporter under the control of an internal ribosome entry site
(IRES) from hepatitis C virus (HCV) (Fig. 1B). Ren expression
serves as an internal control for nonspecific translational inhibition
by IFIT1. Titrating human IFIT1 into these extracts at concen-
trations ranging from ∼30 nM to 5 μM showed that IFIT1 could
inhibit Cap0-dependent translation with IC50 values of ∼50–
200 nM (Fig. 1C, and other figures herein). Interestingly, addition
of IFIT1 after the reporter was preincubated with translation ex-
tracts for 10 min resulted in its inhibitory activity being reduced by
more than an order-of-magnitude (IC50 > 5 μM), presumably
because of the formation of a closed-loop mRNP that facilitates
ribosome reinitiation (28). This result suggests that optimal
IFIT1 activity in vivo is probably only realized in cells that are
already expressing the protein before infection, as might be the
case for cells activated by IFN signaling in a paracrine manner.
In all cases, cap-independent translation of Ren was reduced
by at most 15–20%, which is likely because of nonspecific binding
of IFIT1 to either the IRES, ribosomal RNA (19), transfer RNA
(19), or translation factors (e.g., eIF3e) (29). This finding is in
contrast to one report showing nearly complete inhibition of
HCV–IRES-mediated translation by 600 nM IFIT1 in rabbit
reticulocyte lysates (30). This discrepancy may be attributed to
differences in translation efficiency between Krebs extracts and
rabbit reticulocyte lysates. Finally, titration of IFIT5 in these
assays did not produce the same level of translational inhibition
(Fig. S1D) (IC50 ≥ 5 μM), consistent with the notion that
IFIT5 cannot specifically bind capped-RNA. Taken together,
our data are consistent with an IFIT1 antiviral mechanism that is
dependent on the recognition of mRNA cap structures to com-
pete with eIF4F (18, 19).
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Fig. 1. RNA binding and inhibition of in vitro translation by human IFIT1.
(A) EMSAs between human IFIT1 and capped-RNA visualized by SYBR Gold
staining. Cap0-MHV, first 41 nt of MHV strain A59; Cap0-HCoV, first 42 nt of
HCoV strain 229E; Cap0-GGG42, ACU to GGG modification of HCoV. The RNA
secondary structure minimum free energy (kcal/mol) and 5′-overhang length
(ovg) are indicated (see also Fig. S1B). (B) Schematic of bicistronic mRNA
reporter. (C) Translation assay with IFIT1 titrated into Krebs extracts pro-
grammed with Cap0/m7Gppp reporter, and titration following a 10-min
preincubation of the reporter with extracts. FF and Ren luciferase (luc.) ac-
tivities at each concentration were normalized against buffer control, which
was set to 1. Data represent the mean of two independent measurements
performed in duplicate ± SD.
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Overall Structure of Full-Length Human IFIT1. To gain insight into the
mechanisms of viral RNA binding by IFIT1, we initially crystallized
RNA-bound, full-length, wild-type human IFIT1 (residues 1–478) in
complex with short PPP- and m7Gppp-containing oligoadenosines.
The IFIT1–RNA complex purified and crystallized as a dimer with
two molecules in the asymmetric unit, but diffracted X-rays to only
∼2.7 Å. To improve the resolution, we mutated the dimerization
interface at the C-terminal end of the protein to produce a
monomeric version that crystallized in a different space group and
diffracted X-rays to 1.58-Å resolution (Table S1). The overall folds
of the wild-type and monomeric mutant are essentially the same
(rmsd 0.35 Å). Henceforth, we describe only the high-resolution
structures with respect to RNA binding, whereas all functional
assays were performed with wild-type protein.
Human IFIT1 is made up of 23 α-helices, 18 of which form
9 TPR motifs that together form three distinct subdomains
interrupted by non-TPR structural elements (Fig. 2 A and B and
Fig. S2 A–C). The overall structure is similar to the previously
determined RNA-bound structure of human IFIT5 (rmsd 1.9 Å)
(Fig. S2D) and the N-terminal region of human IFIT1 (rmsd
0.8 Å) (Fig. S2E) (13). The subdomains are arranged to form a
clamp-shaped structure with a central RNA-binding tunnel that is
∼30–40 Å in length and 12–19 Å in width, accommodating only
ssRNA with a total of five nucleotides (cap + four RNA nucleo-
tides) (Fig. 2 B–D). As with IFIT5, a pair of long non-TPR pivot
helices connect the second and third subdomains and likely
function in an analogous fashion to regulate closure of the protein
around the RNA (13) (Fig. S2C). About 30–40% of the tunnel
volume is occupied by bound water molecules (Fig. 2E), which
appears to be an important facet for recognition of different RNA
sequences and structures (discussed below). We demarcate four
distinct regions of the tunnel according to their role in RNA
binding: (i) the cap-binding pocket, which houses the N7-meth-
ylguanosine moiety; (ii) the triphosphate channel, which links the
cap-binding pocket to the 5′-end of the RNA; (iii) the first di-
nucleotide (N1 and N2), where the presence of 2′-O methylation
is sensed; and (iv) the second dinucleotide (N3 and N4), where the
requirement for single stranded 5′-ends is reinforced.
The IFIT1 RNA-Binding Tunnel Houses a Functionally Distinct Cap-
Binding Pocket. IFIT1 and IFIT5 were previously characterized
as PPP-RNA binding proteins (17), although more recent
evidence revealed that the primary role of IFIT1 is in binding
capped-RNA. Conversely, the role of IFIT5 remains restricted
to recognition of 5′-phosphorylated RNAs (13, 14, 16). The
structure of IFIT1 bound to PPP-RNA revealed that, like IFIT5,
the PPP moiety is ligated by numerous specific electrostatic
interactions from protein side chains (Fig. S3 A–C). However,
there are some key differences. IFIT5 recognition of PPP-RNA
uses a positively charged metal ion bound between the α- and
γ-phosphates, which stabilizes a bent conformation of the PPP
facilitated by T37 at the base of the tunnel in IFIT5 (Fig. 3A).
The corresponding position in IFIT1 is occupied by an arginine
(R38), and an ion is no longer part of its PPP binding. This results
in a more extended conformation of the PPP that allows it to
reach toward the entrance of a neighboring unoccupied pocket.
The crystal structure of IFIT1 bound to m7Gppp-RNA revealed
that this adjacent pocket harbors the cap moiety. Whereas most of
the RNA-binding tunnel is positively charged, the cap-binding
pocket is generally more hydrophobic and interactions with the
cap occur predominantly through nonspecific van der Waals
contacts (Figs. 2C and 3B). Surprisingly, we found that the m7G
base adopts both syn- and anti-conformations with approximately
equal occupancies (Fig. 3C and Fig. S3D) (discussed in detail
below). In either conformation, m7G sits atop a tryptophan resi-
due (W147) making π–π stacking interactions, reminiscent of
other cap-binding proteins, such as eIF4E (31) (Fig. 3 D and E).
Additionally, the base is abutted by I183 from the same side as
W147, and on the other side by L46 and T48 emanating from a
flexible loop that forms the outer wall of the pocket, which we
term the “cap-binding loop” (Fig. 3 D and E and Fig. S2F). The
ribose of m7G is similar in the syn- and anti-modes of binding,
adopting an S-type conformation that is stabilized by an intra-
molecular hydrogen bond between the ribose 3′-OH and the
bridging β-phosphate (Fig. S3D). It sits in a pocket formed by Q42,
L46, R187, Y218, I183, and L150 (Fig. 3E), and two ordered water
molecules: the first coordinated by Q42 and the second bridging
the ribose 3′-OH to the backbone carbonyl of W147 (Fig. S3F).
As in PPP-RNA–bound IFIT1, the bridging triphosphate in
the cap-bound structure is in an extended conformation stabi-
lized by numerous electrostatic interactions, although pulled
slightly toward the cap-binding pocket (Fig. 3F and Fig. S3E).
The γ-phosphate interacts with K151, R255, Y218, and R187,
and the β-phosphate is coordinated by K151, R187, and R38.
Additionally, six highly ordered water molecules mediate hy-
drogen bonds with the α- and γ-phosphates (Fig. S3F). Finally,
m7Gppp binding is facilitated by a high degree of interresidue
coordination: for example, R38 is held in place by D34, and
W147 is coordinated by E176 (Fig. S3G).
In IFIT5, although most of these cap-binding residues are
conserved, substitutions at a few key positions render it unable to
bind cap productively. As described above, replacement of R38 in
IFIT1 with T37 in IFIT5 causes it to recognize a more compact
conformation of the PPP in a metal-dependent manner. This
positions the γ-phosphate away from the putative cap-binding
pocket, which draws in several residues, such as Q41 (from helix
α2) and K48 (from the putative cap-binding loop), causing them to
block access to its putative cap-binding pocket (Fig. 3G and Fig.
S3 H and I). Therefore, the formation of a positively charged
RNA-binding tunnel with an accessible and spatially separated
cap-binding pocket in IFIT1 explains, at least in part, why it can
bind capped-RNA, whereas IFIT5 cannot. The preference for an
arginine or threonine on helix α2 is highly conserved among
IFIT1/1B-like and IFIT5-like sequences, respectively (Fig. S3J),
and the identity of this PPP bridging residue (Arg or Thr) appears
to play a major role in determining the 5′ specificities of IFIT1/1B- or
IFIT5-like proteins. Interestingly, a small group of mammalian
IFIT5-like proteins retain an arginine at this position; these se-
quences probably have a hybrid IFIT1/IFIT5 character, and possibly
resemble an ancestral IFIT1/IFIT5 precursor protein, because they
all belong to nonplacental mammals (e.g., opossum and platypus)
(Fig. S3K).
IFIT1 Can Nonspecifically AccommodateMultiple Forms and Conformations
of the Cap. The high-resolution structure of the monomeric
IFIT1 mutant (1.58 Å) allowed us to unambiguously build two
conformations for the m7G base that are consistent with the
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(A) Schematic of IFIT1 subdomains. (B) Cartoon representation of human
IFIT1 colored by subdomain (SD) and surface representation of the tunnel
(dark red) determined by CAVER (50). (C) Cross-section of IFIT1 colored by
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electron density, which has a relatively symmetric shape because of
an ∼180° rotation about theN-glycosidic bond connecting the base
to the ribose. Multiple base conformations were also evident in the
lower-resolution wild-type m7Gppp-RNA cocrystals. This results
in the interactions at the base periphery being quite distinct in
the two conformations (Fig. 4A). Notably, there are no direct
hydrogen bonds from the protein toward the base in either
conformation, but there are a small number of water-mediated
interactions. In the anti-orientation, N3 of the base is weakly
hydrogen bonded to a water molecule that is coordinated by
Q42. The N7-methyl (C7) and O6 groups make van der Waals
contacts with N216, and the remainder of the base is partially
oriented toward water molecules near the proximal opening of
the tunnel leading to bulk solvent. In the syn-orientation, the
N7-methyl and O6 are instead pointing toward the bulk solvent,
whereas N2 is nestled between Y218 and N216.
Because of the presence of the N7-methyl group on m7G, it
acquires a delocalized positive charge on its imidazole ring that
could in principle enhance the stacking with W147 through ad-
ditional cation–π interactions (31, 32). However, the geometry of
cation–π stacking changes with the base orientation (Fig. 4A).
Whereas the anti-conformation places the positive charge at an
angle away from W147, the syn-conformation places it directly
over the indole ring of W147. To test whether N7-methylation and
associated positive charge controls cap orientation, we determined
the structure of Gppp-RNA (lacking the N7-methyl group) bound
to IFIT1 (1.7 Å) (Fig. 4B and Fig. S4A). Here, the base exists only
in the anti-conformation, indicating that the ability of the base to
adopt two conformations depends, at least in part, onN7-methylation.
The presence of two base conformations is also determined by the
chemical environment surrounding the base, because the structure
of an N216 mutant of monomeric IFIT1 (N216A) bound to
m7Gppp-RNA also resulted in the base adopting only the anti-
conformation (Fig. S4B).
Despite these observations, IFIT1 appears not to be selective
for N7-methylation. In fact, gel-shift assays suggest that Gppp-
RNA binding is, in some cases, more efficient than m7Gppp-
RNA binding (Fig. S4C) (18, 19), in stark contrast to the case
with eIF4E, whose cap binding is strongly dependent on proper
methylation (31). In the absence of the methyl group, the gua-
nine ring moves closer to N216, making a hydrogen bond with it
through O6 (Fig. 4B, Left), although removing this hydrogen
bond through mutation (N216A or N216D) does not weaken
Gppp-RNA binding (Fig. S4D). Interestingly, the water structure
surrounding Gppp-RNA changes compared with m7Gppp-RNA,
such that almost all hydrogen bond donor and acceptor sites on
the unmethylated base are now satisfied (Fig. 4B, Right), and this
may be a contributing factor for maintaining strong Gppp-RNA
binding (relative to m7Gppp-RNA).
The physiological relevance of Gppp-RNA binding by IFIT1 is
unclear, but one possibility is that it may facilitate targeting of
transient intermediates formed during viral mRNA capping. We
therefore tested IFIT1 activity in extracts programmed with a
Gppp-capped reporter (Fig. S4E). In this system, although
overall translation is less efficient than in Cap0-programmed
extracts, translation initiation still proceeds through binding of
the cap-proximal nucleotides via eIF4G (33). IFIT1 titration
resulted in translational inhibition similar to m7Gppp-capped
mRNA (IC50 ∼ 200 nM), highlighting the importance of binding
not only the cap, but also the proximal nucleotides to provide
additional affinity to allow competition with eIF4F (19).
Because cap binding does not rely on any guanine-specific hy-
drogen bonds, we wondered whether IFIT1 could also recognize
Appp-capped RNAs. Indeed, IFIT1 can bind Appp-RNA (Fig.
S4F) and inhibit translation initiation from an Appp-capped re-
porter (IC50 ∼ 500 nM) (Fig. S4E). Thus, it appears that IFIT1 has
evolved to recognize not only canonically capped mRNA, but
rather diverse 5′-5′ linked base modifications of the mRNA
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through relatively nonspecific interactions in the pocket. The
notion of lack of specificity is underscored by the structure of
IFIT1 with PPP-RNA, where the cap-binding pocket is occupied
by PEG (polyethylene glycol) molecules from the crystallization
solution, which form interactions that mimic cap binding
(Fig. S4G).
Mutational Analysis of Cap Recognition. To test whether our
structural findings are functionally valid, we mutated several
residues involved in cap binding and assayed them in fluorescent
gel-shift binding assays (with m7Gppp-43 RNA) (Table S2)
and the translational inhibition assays described above (Fig. 5 and
Fig. S4I). Both R38A and K151M are critical for binding, and
K151M reduces IFIT1 inhibitory activity by one to two orders-of-
magnitude (IC50 > 5 μM). Y218A and Q42A weakened binding
to capped RNA and reduced IFIT1 inhibitory activity. N216A retains
full binding to m7Gppp-RNA, indicating that the N216–cap
interactions (e.g., with the N7-methyl) are dispensable. W147 is
perhaps the most important residue inside the cap-binding pocket
as W147M essentially abolished m7Gppp-RNA binding, whereas
mutation to another aromatic residue (W147F) largely retained
binding. Accordingly, W147M reduced IFIT1 translation inhibition
∼40-fold, and W147F mostly retained inhibitory activity (compared
with W147M). Mutation of E176, which coordinates W147, had
similar effects as W147F. From the cap-binding loop, T48 was
deemed dispensable, but L46 was required for optimal binding and
translational inhibition. All cap-binding pocket mutants tested here
retained binding toward PPP-RNA, except for R38A and K151M
(which target the PPP moiety), indicating that the protein fold was
not disrupted by the mutations (Fig. S4J). Taken together, the data in
the mutational analysis confirm the importance of cap binding and
the role of the RNA-binding tunnel in mediating translational in-
hibition by IFIT1.
Our results are in agreement with previous mutational binding
assays based on in silico modeling (19). In this model, Phe-
45 and Tyr-50 from the cap-binding loop were also predicted to
interact with the base; however, our structures reveal that these
two residues are distal from the m7G moiety and are probably
important for maintaining subdomain contacts, or helping pre-
organize the cap-binding loop (Fig. S4K).
The Cap-Binding Mechanism Is Conserved in IFIT1 and IFIT1B Proteins
Across Mammalian Evolution. The mode of cap binding identified
here likely applies to all mammalian IFIT1- and IFIT1B-like proteins,
as the residues involved in N7-methylguanosine triphosphate
recognition are highly conserved (Figs. S4M and S5). Two notably
prevalent differences in cap-binding residues compared with human
IFIT1 include Q42 and N216, which are replaced with a glutamate
and aspartate, respectively, in many of the orthologs and paralogs
(including human IFIT1B). Both substitutions are conservative,
because neither would disrupt hydrogen-bonding patterns nor
interfere with the van der Waals interactions with the cap. We
tested this by carrying out an EMSA between m7Gppp-RNA and
IFIT1 N216D or IFIT1 Q42E (Fig. S4L). Whereas N216D had no
impact on RNA binding, Q42E weakened the interaction and in
translation assays, Q42E reduced IFIT1 activity similarly to Q42A
(Fig. 5B, Right). In other IFIT1-like proteins, such as rabbit
IFIT1 and rabbit IFIT1B [both of which bind m7Gppp-RNA with
∼20 and 10 nM affinity, respectively (19)], the natural Q42E
variation is likely overcome by compensatory interactions.
Unlike IFIT1B from other species, human IFIT1B lacks an
apparent function in RNA binding (12). Sequence comparison
shows that, along with Q42E, human IFIT1B has acquired ad-
ditional substitutions that could impact RNA recognition:
L150 is replaced with an Ala, which would affect cap ribose in-
teractions, and R255 with Gln, which would disrupt a salt-bridge
with the γ-phosphate (Fig. 3 E and F). Supporting this theory,
mutation of R255 in human IFIT1 (R255M) was shown to dis-
rupt capped- and PPP-RNA binding (13, 18). On the other hand,
mice lack a bona fide IFIT1 ortholog and instead encode three
copies of IFIT1B-like proteins (12), currently annotated as
mouse Ifit1, mouse Ifit1b, and mouse Ifit1c (Fig. S5). Mouse
GpppGppp / m7G anti
+
m7G syn
+
m7G anti
§
*
N7N2
N1
O6O6
N2
N3
N9
N1
O6
C7
C7
N9
N1 O6
N2
N216
Y218
W147
Q42
N216
Y218
W147
Q42
N216
Y218
W147
Q42
N216
Y218
W147
Q42
N3
N3
A
B
Fig. 4. IFIT1 can accommodate multiple forms and conformations of the cap.
(A) m7G base interactions at its periphery in the anti- or syn-modes of binding.
The water H-bonded to Q42 (*) is 3.3 Å away from N3 in the anti-mode.
(B, Left) The Gppp-moiety adopts only anti, and approaches N216 to form a
weak H-bond through O6; m7Gppp-RNA bound IFIT1 is superposed in gray.
(Right) The water structure surrounding the G moiety changes compared with
m7G, and satisfies almost all H-bond donor and acceptor groups. The arrows
depict the movement of waters from the m7Gppp-bound form (gray circles)
to the Gppp-bound form (red spheres). The water molecule H-bonded to
Q42 and N3 becomes more ordered in the Gppp-RNA structure (same resolu-
tion and crystal form but B-factor decreases from 28 Å2 to 15.3 Å2). The water
at N7 (§) appears only in the Gppp-bound form. The water at N1 appears to be
in two conformations and was modeled as two water molecules.
FF
Ren
IFIT1 Q42A Q42E Y218A K151M
0.2
0.2
0.4
0.6
0.8
1.0
1.2
0.4 0.6 0.8 1.0
[Protein]   M
R
el
at
iv
e 
Lu
c.
 C
ou
nt
s
5.0
FF
Ren
IFIT1 E176A W147F L46A W147M
0.2
0.2
0.4
0.6
0.8
1.0
1.2
0.4 0.6 0.8 1.0
[Protein]   M
R
el
at
iv
e 
Lu
c.
 C
ou
nt
s
5.0
0
IFI
T1
K1
51
M
R3
8A
W1
47
M
W1
47
F
E1
76
A
Y2
18
A
Q4
2A
N2
16
A
L4
6A
T4
8A
20
40
60
80
100
%
 B
ou
nd
(R
ela
tiv
e t
o I
FIT
1)
10 nM m7Gppp-43-pCp-Cy5
- IFI
T1
K1
51
M
R3
8A
W1
47
M
W1
47
F
E1
76
A
IFI
T1
Y2
18
A
Q4
2A
N2
16
A
L4
6A
T4
8A
Bound
300 nM
Protein
Free
RNA
A
B
Fig. 5. Functional validation of cap recognition. (A) Mutational analysis of
cap-binding residues investigated by fluorescent EMSA with 3′-end–labeled
(pCp-Cy5) RNA. (Left) Quantification of percent bound (Upper band, Right)
for each mutant normalized against IFIT1. Data represent the mean of three
independent measurements ± SD. (B) In vitro translation assays with RNA
binding mutants and Cap0 reporter. Data represent the mean of two
measurements ± SD.
E2110 | www.pnas.org/cgi/doi/10.1073/pnas.1612444114 Abbas et al.
7. Publication 2
114
Ifit1b and Ifit1c harbor several substitutions that would disrupt
RNA binding, such as R255G and Q42T in both, and R187H in
Ifit1b (Fig. S5). Consistent with this finding, pull-downs showed
that mouse Ifit1c cannot bind capped RNA directly (18).
IFIT1 Cap Binding Is Distinct from Canonical Cap-Binding Proteins.
The IFIT1 cap-binding mechanism described here is quite distinct
from canonical cap-binding proteins such as eIF4E (34), cap-
binding complex (CBC) (35), and VP39 (vaccinia virus N1 2′-O
MTase) (36). Through convergent evolution these proteins
evolved a highly specific cap-binding slot between two aromatic
side-chains that engage the methylated guanine in a cation–π
sandwich (31). Charge–charge interactions with the delocalized
positive charge and van der Waals contacts with the N7-methyl
also play a role (31). In these proteins, the absence of N7-
methylation and associated positive charge on the base results
in >100-fold loss in binding affinity (37). These proteins also rely
on hydrogen bonds targeting groups at the m7G base periphery.
The cumulative effect of these restrictions results in highly specific
recognition of the cap in a single anti-conformation of m7G (Fig. 6).
In contrast, IFIT1 engagement of the cap is relatively less
specific, permitting both syn- and anti-base orientations, as de-
scribed above. Although IFIT1 does use one aromatic residue for
cap stacking, the remainder of its sandwich is formed by aliphatic
side chains (Leu-46, Thr-48, and Ile-183) rather than another ar-
omatic residue. Therefore, the lack of an electron-rich, aromatic
cap-binding slot reduces the dependence on an electron-deficient,
N7-methylated base. Additionally, protein contacts with the N7-
methyl are dispensable (e.g., the N216A mutant), and they are
altogether absent when the cap is in the syn-configuration. Im-
portantly, IFIT1 lacks any sequence specific hydrogen bonding
from protein residues, and instead uses a more plastic, water-
mediated hydrogen-bonding network for base recognition.
Finally, at physiological pH m7G exists in an equilibrium be-
tween two forms: a positively charged “keto tautomer” and a
zwitterionic “enolate tautomer” (in which N1 is deprotonated)
(Fig. S4H) (34). The canonical cap-binding proteins are highly
selective for guanine as the base and in particular, its keto form.
These aspects are enforced by two elements: (i) the cation–π
sandwich, which is only compatible with an electron-deficient,
positively charged keto tautomer (38); and (ii) Asp or Glu res-
idues at one end of the cap-binding slot, which hydrogen bond
with a protonated N1 and the N2-amino group. Conversely,
IFIT1 does not form any keto- or enolate-specific interactions
with the base, suggesting that IFIT1 is not selective for the
tautomerization state, reinforcing the lack of guanine specificity.
Binding of Cap-Proximal Nucleotides.Recognition of the four RNA
nucleotides following the cap is conformation-specific and can be
divided into two distinct dinucleotide groups diverging between
N2 and N3 (Fig. 2 C–E). The RNA backbone lies along the
superhelical axis of the protein, and is recognized by specific
hydrogen bonds and salt bridges from protein residues targeting
the 5′-phosphates and 2′-hydroxyls of N2 and N3 (Fig. S6 A and B).
In contrast, recognition of the bases is predominantly through
sequence-nonspecific van der Waals and stacking interactions. The
first dinucleotide (N1 and N2) adopts geometry similar to CpG
dinucleotides found within Z-form RNA and UUCG tetraloops
(39), and is tightly sandwiched between multiple protein residues
(Fig. S6 A and C). The second dinucleotide (N3 and N4) adopts
A-form helical geometry with the bases also stacked upon each
other and abutted by protein residues from above and below (Fig.
S6 B andD). The large water network inside the tunnel interacts with
all groups of the RNA, and mediates both intermolecular protein–
RNA and intramolecular RNA–RNA interactions (Fig. S6E).
Interestingly, a large part of this extensive water network is
involved in protein–base contacts, allowing IFIT1 to recognize a
wide variety of RNA sequences that may exist at the 5′-end of
viral RNA. A small degree of sequence-dependent binding affinity
variation may exist because there are two adenine-specific hydrogen
bonds at N2 and N4 (Fig. S6 A and B), although RNA binding assays
show that adenosines are not strictly required at these positions.
The 3′-end of the RNA (N4) emerges from the C-terminal
opening of the tunnel and points toward a positively charged,
solvent-exposed groove formed by the pivot helices and the third
subdomain (Fig. 7). This surface is contiguous with the RNA-binding
tunnel and also appears to contribute to RNA interactions be-
cause the analogous region in IFIT5 can apparently bind tRNA
(14). In IFIT1, the groove does play some role in RNA binding,
as primer-extension toe-printing assays suggested that IFIT1 has
a 6- to 8-nt footprint at the 5′-end of mRNA, and mutational
analysis of this region had an impact on mRNA binding (19).
However, cocrystal structures of IFIT1 with longer oligonucle-
otides (6–8 nt in length) revealed extra electron density for only
the 5′-phosphate of a fifth nucleotide, as was shown for IFIT5 (13),
suggesting that only the first four nucleotides are stably bound by
IFIT1, whereas residues in the positively charged groove probably
contribute to nonspecific RNA binding.
IFIT1 Senses Ribose 2′-O Methylation at N1 and N2. The mRNA of
higher eukaryotes is normally modified by ribose 2′-O methyl-
ation at N1 and N2 (40). Whereas all cellular mRNAs are
methylated at N1 in the nucleus by the endogenous Cap1-
methyltransferase (CMTr1) (2), ribose methylation at N2 arises
from secondary methylation in the cytoplasm through the action
of CMTr2 (3, 41), and accompanies N1 methylation on up to
50% of cellular mRNAs (42, 43). N1 ribose methylation is a
molecular determinant of self that can protect mRNA from
IFIT1/IFIT1B recognition (18, 19), but the role of N2 methylation
in this process is unknown. To gain additional insight into self- vs.
nonself-mRNA discernment by IFIT1, and to explore the
uncharacterized role of ribose N2 methylation in this process, we
examined the interaction between human IFIT1 and differentially
methylated RNA. Note that, to distinguish the naturally occurring
Cap1 and Cap2 structures (m7GpppNmN- and m7GpppNmNm-)
from capped RNAs that contain ribose N2 methylation only
(m7GpppNNm-), we refer to the latter as Cap0N2Me-RNA.
When bound to IFIT1, N1 and N2 adopt a rare Z-RNA–like
conformation that is dependent on their respective ribose con-
formations (Fig. S6F) (39). Whereas N2 is in the favorable
C3′-endo conformation, N1 adopts a C2′-endo conformation and
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places its 2′-OH in close proximity to the side chains of two
highly conserved residues, R187 and Y157 (Fig. 8A and Fig.
S6A). Modeling of ribose 2′-O methylation on N1 to mimic
Cap1-mRNA shows that the methyl group would clash with these
protein residues (Fig. 8A). Rotating the methyl group away in-
troduces a steric clash with the RNA itself and interferes with the
water network. Interestingly, N2 ribose methylation is also pre-
dicted to disrupt RNA binding to IFIT1, because of hydrogen
bonds with H289 and steric hindrance by Q290 (Fig. 8A and Fig.
S6A). Thus, the IFIT1 tunnel is restricted to interact with RNAs
not methylated at these 2′-hydroxyls.
Consistent with this finding, either N1 or N2 methylation of
HCoV and GGG42 RNAs is sufficient to disrupt binding with up
to 2.5 μM IFIT1 (Fig. 8B and Fig. S7 A and B). Surprisingly, at
the same concentrations, individual N1 or N2 methylation only
partially reduced the interaction between IFIT1 and MHV
RNA, and combining both was required to fully abolish binding
for this sequence (Fig. 8B and Fig. S7 A–C). This RNA-
dependent effect is likely because of the longer overhang and
decreased secondary structure stability of the MHV sequence
compared with HCoV/GGG42 (Fig. 1A and Fig. S1B), allowing
it to maintain relatively strong binding to IFIT1, even when
modified with a single ribose methylation, and requiring the
additive effect of multiple methylations (N1+N2) to avoid
IFIT1 recognition. However, we cannot rule out the existence of
RNA-sequence or other structural elements within MHV that
intrinsically enhance its affinity for IFIT1. At higher protein
concentrations (5 μM IFIT1) where nonspecific interactions may
play a role, the additive effects of N1+N2 ribose methylations
also became apparent for the GGG42 RNA (Fig. S7 D and E).
Consistent with the above findings, single N1 or N2 methylation of
the reporter mRNA reduced IFIT1 inhibitory activity in translation
assays by ∼10-fold (IC50 ∼ 1 μM) (Fig. 8C), whereas translation of
Cap1- and Cap0N2Me-mRNA was still strongly inhibited by 5 μM
IFIT1. This finding intriguingly suggests that N1- or N2-methyl steric
hindrance can be overcome at very high IFIT1 concentrations, pos-
sibly from nonspecific RNA interactions contributed by the solvent
exposed groove of IFIT1. As before, combining N1 and N2
methylations (Cap2 reporter) resulted in a striking rescue of trans-
lational inhibition, restoring FF levels to 90% even in the presence
of 5 μM IFIT1 (Fig. 8C). Taken together, our combined structural
and functional analysis confirms the role of N1 methylation in in-
terfering with IFIT1 inhibitory activity, and reveals an analogous
function for N2 methylation. Importantly, our data suggest that the
combination of N1 and N2 methylation, as found in nearly half of
endogenous mRNAs, produces an additive and potentially syner-
gistic protective effect against IFIT1 recognition, which is particu-
larly evident under circumstances where IFIT1 can overcome
individual 2′-O methylation in an RNA-dependent or protein
concentration-dependent manner.
To further confirm the importance of 2′-O methyl sensing for
IFIT1 activity, we mutated the residues predicted to clash with
N1 or N2 ribose methylations, and tested their impact on RNA
binding and translational inhibition (Fig. 8 D and E). At N1,
Y157F had only a minor effect on capped RNA binding, but both
R187H and R187A abolished the interaction. At N2, mutating
either H289 (H289A) or Q290 (Q290E) partially reduced binding,
and combining either mutant with Y157F (DM-YH, Y157F/
H289A; or DM-YQ, Y157F/Q290E) completely disrupted bind-
ing. Translation assays also showed reductions in IFIT1 inhibitory
activity for all mutants, with R187H and the two double mutants
having the greatest effect. It should be noted, however, that these
residues are highly conserved (Fig. S4M), and as such, play an
integral role in general RNA binding that extends beyond 2′-O
methyl sensing (Fig. S6 A and B). Thus, capped-RNA recognition
and 2′-O methyl sensing by IFIT1 are two tightly linked processes
that have likely coevolved.
Functional Validation of IFIT1 Activity Against 2′-O Methyltransferase
Deficient Human Coronavirus. Human IFIT1 has been shown to in-
hibit replication of viruses lacking N1 ribose 2′-O methylation, such
as HCoV 229E bearing a D129A (DA) mutation in its viral 2′-O
MTase gene (18). Therefore, to functionally validate our results in a
biological context, we tested the antiviral activity of IFIT1 RNA-
binding mutants against wild-type HCoV 229E and HCoV 229E
DA. First, we verified that the IFIT1 mutants used in cell-based
assays (R187H, W147M, Y157F, and Q290E) disrupted the
interaction with Cap0-HCoV RNA (Fig. S7F). Next, we recon-
stituted Flp-In T-REx 293 IFIT1 knockout cells with human
IFIT1 or IFIT1 mutants, and assayed HCoV growth in these cells
(Fig. 8 F and G). Although expression of a control protein (GFP)
led to comparable accumulation of both wild-type and DA virus in
the supernatant of infected cells, expression of IFIT1 significantly
reduced growth of the DA mutant virus, but not wild-type virus
(Fig. 8F). In contrast, IFIT1 R187H, which disrupts interactions
with the cap ribose and bridging triphosphate (Fig. 3 E and F),
was unable to impair HCoV 229E DA virus growth (Fig. 8F).
Similarly, W147M, which disrupts cap recognition, or Y157F and
Q290E, which impair binding to Cap0-HCoV RNA (Fig. S7F), lost
their antiviral activity against HCoV 229E DA (Fig. 8G). Thus,
IFIT1 binding to 2′-O unmethylated viral RNA is required for its
antiviral properties.
Discussion
The ability of many viruses to cap their mRNA and mimic the
host’s allows them to hijack a cell’s translational machinery and
replicate new virus particles. To counteract this, host cells have
evolved as part of their antiviral program, the IFIT proteins. By
competing with eIF4E/eIF4F for binding to capped RNA,
IFIT1 can prevent viral propagation by latching onto the ends of
mRNA and preventing assembly of ribosomal initiation com-
plexes (18, 19). Whereas recognition of the cap by eIF4E and
other cap-binding proteins occurs in a highly specific manner (31,
37), we surprisingly found that recognition of the cap moiety by
IFIT1 is instead nonspecific with regards to both sequence and
structure. Through its highly water-filled cap-binding pocket,
IFIT1 can accommodate not only bona fide cap in different
orientations, but also an unmethylated cap, adenine cap, and
presumably other structures too. This built-in plasticity may in
part be to allow IFIT1 to maintain a broad spectrum of antiviral
activity, and to thwart the ability of viral structures to rapidly
evolve. Another possibility is that IFIT1 genes simply have not
had enough time to evolve exquisite cap specificity, because they
emerged relatively recently in evolution [jawed vertebrates (12)]
compared with eIF4E and CBC, which are essential genes in all
eukaryotes (34, 35). Regardless, the penalty for this plasticity is
likely a reduction in affinity for the cap moiety and in this re-
spect, the recognition of nucleotides beyond the cap provides
IFIT1 the additional affinity required to compete with an oth-
erwise very tight eIF4F–5′-cap complex.
The recognition of cap-proximal nucleotides by IFIT1 also plays
a critical role in discerning self from nonself. Our structural
analysis revealed that IFIT1 forms a tight interacting surface
around the ribose 2′-hydroxyls of N1 and N2, thus preventing
recognition of endogenous mRNAs methylated at these positions
SD IIIPivot
45˚
SD III
Pivot
SD II
Groove
SD I
Fig. 7. IFIT1 forms a positively charged, solvent-exposed RNA binding
groove. See Fig. S5 for residues in this region.
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and restricting IFIT1 activity to unmethylated viral mRNAs. This
finding is supported by a comprehensive gel-shift analysis that
showed a preference for recognizing Cap0 structures over N1 or
N2 methylated RNA, in vitro translation assays that showed a
reduction in IFIT1’s ability to inhibit translation of N1 or N2
methylated mRNA reporters, and human coronavirus infectivity
assays that showed enhanced IFIT1 antiviral activity when viral
N1 methylation was mutated. In this way, IFIT1 effector function
complements RIG-I receptor activity (summarized in Fig. S7H–J),
as RIG-I detects blunt-ended, base-paired PPP- and Cap0-RNAs
to up-regulate IFIT1 and other ISGs (8, 9).
Cellular N1 methylation was generally thought to be the pri-
mary determinant of self, protecting endogenous mRNA from
IFIT1 recognition, but we discovered that the ability to discern
between Cap0 and Cap1 structures is diminished for one of our
RNAs (MHV) (Fig. 8B), an effect that is possibly linked to its 5′-
sequence or secondary structure. This finding is in accordance
with a recent study by Daugherty et al., who demonstrated that
human IFIT1 can target both Cap0 and Cap1 mRNAs when
overexpressed in a yeast system (12). Furthermore, while this
manuscript was under revision, Young et al. similarly showed
that N1 methylation of a reporter gene only partially reduced its
sensitivity to human IFIT1 in an in vitro translation system (44).
Interestingly, using viral mRNA in the same system, Young et al.
also noted potential RNA-dependent effects for N1 methylation.
Taken together, these observations lead to the conclusion that
N1 methylation alone may not be enough to protect all endoge-
nous mRNAs from IFIT1, and that there are other determinants
of self that govern IFIT1 activity.
Our structural and functional analysis reveals that N2
methylation by CMTr2 could fulfill this role, providing an
additional safeguard against aberrant recognition of mRNAs
that are otherwise susceptible to IFIT1 (Fig. 8B). However, as
Cap2 structures are not as ubiquitous as Cap1 (40), other elements
may prevent self-recognition. For example, actively translating
mRNAs are generally found in preformed mRNP complexes and,
as indicated by our order-of-addition experiment (Fig. 1C), would
be protected from IFIT1 competition. Similarly, newly synthesized
mRNAs undergo a pioneer round of translation directed by the
CBC (45), which may also offer protection from IFIT1. Adenosine
N6-methylation of the first transcribed nucleotide is another
modification that accompanies ribose N1 methylation on ∼20–
30% of cellular mRNAs, in the form of N6,O2′-dimethyladeno-
sine (m6Am) (46, 47). Our structure suggests that m6Am could
protect self-mRNAs by disrupting water-mediated interactions
and impinging on nearby residues (Fig. S6 A and E), and thus merits
further investigation. Finally, cap-proximal secondary structure
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elements could combine with mRNA modifications to further
prevent self-recognition.
To what extent do viruses exploit these mechanisms to alter
IFIT1 activity? Our observations support the model whereby
viral N1 methylation evades or dampens IFIT1 activity (Fig. 8 F
andG), and is consistent with previous studies showing enhanced
sensitivity of coronaviruses and flaviviruses to IFIT1 when viral
N1 methylation was mutated (18, 23, 24, 26). Similarly, Young
et al. recently showed that parainfluenza virus type 5 (PIV5) was
more sensitive to human IFIT1-mediated restriction than PIV3,
partly because PIV5 mRNAs were not completely N1-
methylated during infection (44). On the other hand, vesicular
stomatitis virus (VSV) has been shown to uniformly N1-
methylate its mRNAs in vivo (48, 49), yet it remains sensitive
to IFIT1 restriction (12). One explanation is that the short and
potentially unstructured 5′ UTRs of VSV mRNAs could allow
IFIT1 to overcome N1 methylation (as described here for MHV
RNA). Alternatively, VSV mRNAs may display another pattern
specifically recognized by IFIT1 (as proposed by Daugherty
et al.), such as RNA-sequence or -structural elements (12).
Further work is needed to validate either notion, and to deter-
mine if this ability to overcome viral N1 methylation is an ad-
aptation that allows IFIT1 to target other Cap1-containing
viruses, or if it is restricted to VSV and related viruses.
IFIT1B (which includes mouse Ifit1) is the only other IFIT
family member known to specifically recognize capped RNAs to
inhibit viral replication (18, 19). Our analysis supports the notion
that both proteins use a similar mode of cap-recognition, and
thus should display overlapping antiviral activities. However,
recent evidence suggested otherwise (12). Based on our struc-
tural and functional data, we propose that both IFIT1 and
IFIT1B can target Cap0-containing viruses, but they may differ
in their sensitivity to cap-proximal modifications, such as meth-
ylation, RNA-sequence, or RNA-structure. These differences
and underlying molecular mechanisms are not entirely clear yet,
but one possibility is that the ability to overcome N1 methylation
in an RNA-dependent manner could distinguish IFIT1 from
IFIT1B proteins, and may explain why IFIT1 overexpression
inhibited wild-type VSV replication (a Cap1-containing ssRNA
virus), whereas IFIT1B overexpression did not (12). Regardless,
in humans IFIT1B appears to be nonfunctional, and has been
deleted or pseudogenized in several other mammals, consistent
with the notion that widespread viral evasion strategies (e.g.,
N1 methylation) have generally defeated IFIT1B (12), whereas
IFIT1 was retained possibly because of its adaptable nature.
Taken together, through a relatively nonspecific cap-binding
pocket and a potentially plastic RNA binding mechanism,
IFIT1 appears to have grafted adaptability onto an otherwise
germ-line–encoded member of the innate immune system, to
broadly defend against rapidly evolving viral pathogens. At the
same time, the host evolved multiple mechanisms that combine to
limit detrimental IFIT1 activity against endogenous mRNAs.
Clearly, further work is needed to validate the physiological rele-
vance of these notions, particularly with respect to understanding
how IFIT1 can overcome N1 methylation in an RNA-dependent
manner, the differential specificities of IFIT1 and IFIT1B proteins,
and if viruses exploit CMTr2 and other enzymes to modify their
mRNA and evade IFIT1. Finally, it has been established that
human IFIT1 can form complexes with other IFIT family members
(IFIT2 and IFIT3) and several host factors (17), which could play a
role in modulating self- vs. nonself-mRNA recognition and trans-
lational inhibition. Our structural and functional analysis of IFIT1-
capped RNA interactions will provide a framework for future
structure-guided studies of IFIT function. Moreover, these efforts
will provide important contributions to the development of mRNA
therapeutics and to vaccine design, as emerging research suggests
that rendering viruses more susceptible to IFIT1-like antiviral re-
sponses, by inhibiting their mRNA 2′-O methylation or modifying
their 5′-secondary structure, is a strategy for the rapid development
of live, attenuated vaccines (e.g., refs 21–24).
Materials and Methods
Detailed discussions of the materials and methods used in this study are
provided in SI Materials and Methods.
Protein Expression and Purification. IFIT proteins, RNMT (Human N7-MTase),
and TbMTr2 (Trypanosoma brucei Cap2 MTase) were expressed in
Escherichia coli, and purified by Ni-affinity, ion-exchange, and size-exclusion
chromatography. CMTr2 (Human Cap2MTase) was expressed in Sf9 insect cells
and purified by Ni-affinity and size-exclusion chromatography.
IFIT1 Crystallography. IFIT1 monomeric mutants (L457E/L464E or N216A/L457E/
L464E) were purified to homogeneity and mixed with molar excess chemically
synthesized oligos (see SI Materials and Methods for synthesis, purification,
and MS of oligos) and crystallized in 27–32% (vol/vol) PEG 200, 0.1 M Tris pH
8.1, and 200 mM CaCl2. Crystals were flash-frozen in liquid nitrogen without
additional cryoprotection, and diffraction data were collected at Canadian
Light Source beamline 08ID-1 (Table S1). Initial structures were determined
by molecular replacement, subsequent structures by rigid body refinement.
RNA EMSA. RNAs for EMSAs were prepared using T7 RNA polymerase and pu-
rified by denaturing PAGE. Appp-GGG42 was capped cotranscriptionally; other
modifications were performed with CIP (New England Biolabs), vaccinia capping
enzyme (New England Biolabs), Cap1 2′-O MTase (New England Biolabs), or
home-made CMTr2 or TbMTr2. All 5′ caps and RNA sequences were confirmed
by LC/MS. RNA sequences and mass spec summary are in Tables S2 and S3,
respectively. The 3′-end labeling of m7Gppp-43 with pCp-Cy5 was performed
with T4 RNA ligase (New England Biolabs). For EMSAs, purified proteins and RNA
were mixed at the indicated concentrations in each figure, and resolved by
native PAGE [1× TBE, 10% (vol/vol) gels]. Bands were visualized with SYBR
Gold and UV imaging (unlabeled RNA), or with a Typhoon R3 imager (for
pCp-Cy5 labeled RNA). Band densitometry was performed with ImageJ.
Reporter mRNA Preparation and in Vitro Translation Assay. The bicistronic
reporter (5′-UTR sequence is in Table S2) was in vitro transcribed with
SP6 RNA polymerase in the presence of either m7GpppG, GpppG, or
ApppG RNA Cap Analog (New England Biolabs). N1/N2 methylations were
performed post transcriptionally using mRNA Cap1 2′-O MTase (New
England Biolabs) and/or TbMTr2. In vitro translations were set up at a
final volume of 10 μL with 4 ng/μL reporter mRNA (∼4 nM final) and 1 μL
protein in untreated Krebs-2 extracts, and performed as described in SI
Materials and Methods.
Virus Infectivity Assay. Flp-In T-REx 293 IFIT1−/− cells were cotransfected with
plasmids for IFIT1 and CD13 (HCoV receptor). Cells were treated with
20 units of IFN-β or left untreated and 24 h later infected with HCoV 229E
wild-type and HCoV 229E DA with a multiplicity of infection of 1 and 1.25,
respectively. Eighteen hours postinfection, virus accumulation was tested by
quantitative RT-PCR or TCID50 analysis.
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The arms race between viruses and their hosts greatly advanced both, the viral strate-
gies to exploit the host cell as well as the host defense system. Over the course of
evolution, the host cell developed simple but eﬀective mechanisms to detect and clear
viral pathogens and thereby adapted to the sophisticated strategies viruses themselves
evolved to evade the cellular defense system. The repertoire of host cells include pattern
recognition receptors which are able to speciﬁcally sense viral genetic material, that lacks
features host nucleic acids evolved to have. Moreover, host restriction factors represent
a simple yet eﬀective method to contain virus growth and nucleic acid turnover serves as
an eﬀective instrument to clear the cell from nucleic acids and thereby prohibits further
virus spread. In this dissertation, I identiﬁed novel aspects of the host defense system. In
particular, I present a novel strategy of the host to speciﬁcally degrade viral and further-
more insights into how a restriction factor inhibits translation of capped viral transcripts.
Novel aspects in antiviral immunity
The full potential of antiviral immunity is not yet known. However, in recent years it
became clear that sensing by pattern recognition receptors and the subsequent induction
of cytokines and type I interferons is not the only layer of nucleic acid immunity. Another
layer of complexity was added, when ﬁrst insights revealed speciﬁc degradation of viral
nucleic acids. In general, RNA degradation is a process that is tightly regulated in order
to regulate the abundance of mRNA and to spot aberrant cellular RNAs that need to be
degraded. Targeted degradation of mRNA lowers the expression levels of speciﬁc proteins
and thereby recycles the nucleotides needed for the synthesis of other transcripts the
cell requires. The RNAs degraded by 5’- and 3’-exonucleases also include viral nucleic
acids. However, the proteins involved to speciﬁcally degrade pathogenic nucleic acids
are not known yet. Comparing the RNA degradation mechanisms of eukaryotes and
prokaryotes revealed some striking similarities. mRNAs of both kingdoms are protected
from degradation by either a 5’-cap structure in case of eukaryotes or a 5’-PPP group in
case of bacteria. In order to be degraded, both chemical structures need to be removed.
Notably, removal of the 5’-cap structure by DCP2 and dephosphorylation of the 5’-PPP
group by RppH involves two proteins of the Nudix hydrolase family of proteins. Given
that the genetic material of RNA viruses is chemically very similar to the mRNA of bac-
teria I took this assumption as a starting point to explore potential phosphatases of the
human Nudix hydrolase family to use PPP-RNA as a substrate. In the work presented
here, I could identify a novel mechanism involving NUDT2 that is speciﬁcally preparing
5’-PPP RNA substrates for degradation by the exonuclease XRN1. Furthermore, this
mechanism seems to be universal and demands no speciﬁc sequence or structural feature
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of the RNA substrate. Since the activity of Nudix hydrolases and especially of NUDT2
is conserved throughout evolution, this form or immunity may represent an ancient
defense mechanism. Using Vesicular Stomatitis Virus (VSV) as model virus elucidated
the antiviral capacity of NUDT2 in mouse embryonic ﬁbroblasts and its importance is
highlighted by the impact on the mortality of VSV infected mice that lack the Nudt2
gene. The RNA of VSV serves as an ideal substrate for NUDT2 since its 5’-end is
triphosphorylated and VSV is replicating in the cytoplasm of infected cells. Besides
being localized to the cytoplasm, NUDT2 is also found in the nucleus. Since other
classes of RNA viruses (e.g. IAV) use the nucleus of the host cell for their replication
purposes, NUDT2 could serve as a broad acting surveillance system for viruses bearing
5’-PPP groups. Further studies, including diﬀerent classes of RNA viruses as well as
DNA viruses will give more detailed insights into the speciﬁcity of NUDT2. Already
previously it was shown that the RNA of HCV is degraded in an XRN1 dependent
manner150. However, it was unclear how the 5’-PPP RNA is prepared for degradation
by the exonuclease XRN1 that strictly uses only 5’-monophosphorylated RNA as a
substrate. It was hypothesized by Stanley Lemon and others121;151;152 that an as yet
unidentiﬁed cellular pyrophosphatase would need to remove phosphates from the 5’-end
of viral RNAs to make it amenable for XRN1 cleavage. The mechanism of NUDT2 to
remove phosphates from 5’-PPP RNA substrates to launch RNA degradation represents
the ﬁrst mechanism of a RNA degradation pathway that speciﬁcally targets viral RNAs.
Several publications already emphasized the importance of viral RNA degradation
or implied cellular proteins and pathways relevant for viral RNA degradation. This
included both canonical cellular RNA turnover routes, the 5’-3’ decay mediated by
XRN1 or 3’-5’ degradation by the exosome complex. However, none of the published
data showed a targeted viral RNA degradation. NUDT2 could serve this role, since
5’-PPP RNAs are not present in cells under steady-state conditions and enter the cells
only through virus infection. At the current stage, the observed phenotype is correlative
since we could not show an active degradation of a speciﬁc viral RNA. To address this
point, it would be insightful to develop targeted experiments, for instance pulse-chase
experiments, which allow to unequivocally determine the stability of viral and cellular
RNAs.
The relevance of NUDT2 is as well emphasized by the fact that many viruses evolved
a variety of mechanisms to shield their triphosphorylated RNA ends to evade such a
degradation mechanism. Many viruses hide from NUDT2 by protecting their nucleic
acids with a 5’-cap structure just as their host does. The capping of host mRNAs takes
place in the nucleus, therefore many viruses that replicate in the cytoplasm either achieve
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a cap structure by encoding for their own capping machinery or by abducting it from
cellular mRNAs in a process called cap snatching153. Other viruses like Picornaviruses
bear a structural element at their 5’-end called internal ribosome entry site (IRES) that
could oﬀer a barrier for exonucleases154. Some RNA viruses also protect their RNA by
the attachment of a viral genome-linked protein (VPg). HCV employs an unconventional
mechanism to stabilize its RNA by recruiting miR-122 to its 5’-end. This liver-speciﬁc
miRNA was shown to protect the viral nucleic acids from degradation by XRN1155. In
addition, counter-measures of other plus-strand RNA viruses (e.g. ﬂaviviruses) could be
the formation of membranous replication factories that shield the viral nucleic acids
from cellular proteins156. It is not clear yet, how NUDT2 would gain access to such
cellular compartments or if the impact of NUDT2 on growth of those viruses is indeed
limited by these viral counter-mechanisms. Screening more viruses would enhance our
understanding of the comprehensiveness by which NUDT2 initiates RNA degradation.
An important point to consider is the impact of NUDT2 on the functionality of the
innate immune system. NUDT2 is constitutively expressed and not induced upon
stimulation by type I interferons (Philipp Hubel, unpublished data). However, NUDT2
is removing triphosphates from viral RNAs and may thereby modulate the stimulatory
potential of viral PAMPs. It could well be, that the activity of NUDT2 needs to be
tightly regulated in order to allow a proper immune response besides the clearance of
viral genomic material. This could either involve a kinetic regulation where pattern
recognition receptors like RIG-I ﬁnd enough time to sense their putative ligand and
initiate an antiviral response or a spatial separation of NUDT2 and pattern recognition
receptors in diﬀerent cellular compartments or cytoplasmic sub-compartments induced
by speciﬁc viruses. Moreover, NUDT2 could potentially be held in an inactive state
by other proteins bound to it. Stimulation with cytokines like type I interferons may
abrogate these inhibitory factors and release fully active NUDT2. Identifying potential
interaction partners of NUDT2 by aﬃnity puriﬁcation coupled to mass spectrometry
would give valuable insights into such a potential regulation mechanism of NUDT2
on the protein level. Such ﬁndings could theoretically be used to develop therapeutic
antiviral strategies. Boosting NUDT2 activity by modulating its activity would elevate
the degradation of viral nucleic acids and decrease virus load.
In this PhD work, I chose growth of Vesicular stomatitis virus as functional readout to
discover mammalian pyrophosphatases able to initiate a viral RNA degradation pathway.
Thereby I found exclusively NUDT2 to have an impact on virus growth and the ability
to release phosphates from a triphosphorylated RNA substrate. However, it could well
be that other mammalian Nudix hydrolases have redundant functions. Testing their
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potential on growth of other viruses including viruses with for instance capped nucleic
acids could reveal the importance of other Nudix proteins. Moreover, I cannot exclude
that NUDT2 had redundant function to other proteins. It could be that alternative
cellular phosphatases similarly prepare viral RNA for degradation by nucleases. Most
cellular phosphatases use post-translationally modiﬁed proteins as substrate and were
not shown to be active on RNA. Another prerequisite for 5’-3’ degradation of the RNA
body would be a remaining monophosphate group since OH-RNA cannot serve as
substrate for XRN1.
Further roles of dephosphorylation by NUDT2 in cellular homeostasis
The novel role of NUDT2 introduced here raises the question of cellular triphosphory-
lated RNA substrates for NUDT2. The principal substrate of NUDT2 is the thermal or
genotoxic stress-induced diadenosine tetraphosphate (Ap4A)157. It is synthesized by a
number of proteins including DNA ligases, ﬁreﬂy luciferase and most aminoacyl-tRNA
synthetases158. Besides some other proteins, NUDT2 plays the major role in cleaving
Ap4A to reduce intracellular levels159. Intracellular Ap4A was implicated to act as a
second messenger, as transcriptional regulator and to be involved in the regulation of
DNA replication160;161. 5’-PPP RNA as a substrate for NUDT2 was not indicated so far.
However, with the new role identiﬁed here one could speculate that besides clearing the
cell from viral triphosphorylated nucleic acids, endogenous triphosphorylated RNAs can
serve as substrate as well. Only little is known about the presence of such endogenous
5’-PPP RNAs. Most nucleic acid species generated by the RNA polymerases in the
nucleus are processed and modiﬁed in such a manner, that no stimulatory motif is
present when being exported to the cytoplasm. However, some Pol-III transcripts
including 5S rRNA and many ncRNAs were not shown to be modiﬁed at the 5’-end and
probably bear triphosphorylated 5’-ends. Although, being mostly sequestered in protein
complexes (e.g. 5S rRNA in ribosomes, vault ncRNA in the major vault complex) such
endogenous 5’-PPP RNAs would be highly stimulatory by activating the intracellular
pattern recognition receptor RIG-I. It may be that another essential function of NUDT2
involves rendering such potential stimulatory self-nucleic acids harmless. This would
put NUDT2 on par with nucleases like TREX1 or DNase II that clear the cell from self-
stimulatory DNA molecules and prohibit the development of autoinﬂammation through
a chronic induction of type I interferons. However, several important questions remain
to be solved. In light of improvements of increasingly sophisticated, sensitive and fast
genomics methods, mutations in the genome of patients with type I interferonopathies
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could elucidate the importance of NUDT2 in the onset of autoinﬂammatory diseases.
Moreover, exploring the identity of potential stimulatory endogenous RNA molecules or
the identiﬁcation of triggers that lead to the release or detachment of such RNAs in the
cytosol would greatly enhance our understanding of type I interferonopathies.
Antiviral restriction factor specificity
A further aspect of my work stresses the counter mechanisms cells evolved to contain
viral replication. The restriction factor IFIT1 sequesters capped viral RNAs lacking
methylation marks host mRNAs normally have. By binding to these RNAs the transla-
tion of speciﬁcally viral transcripts is inhibited. Interestingly, the crystal structure of
IFIT1 with capped RNA revealed that the cap-binding pocket is relatively unspeciﬁc.
Besides accommodating the canonical m7G-cap structure, unmethylated cap structures
and adenine caps could as well ﬁt. A stricter speciﬁcity is introduced by a tight tunnel
that excludes methylation on the ribose of the ﬁrst (N1) and second nucleotide (N2).
Previously, N1 methylation alone was thought to be a suﬃcient feature of self. However,
observations from the crystal structure and experimental data of others162;163 suggest
that probably N2 methylation could provide an additional layer of safety to protect
cellular mRNAs from IFIT1 restriction. This novel insights could potentially aid the
development of live attenuated vaccines that only recently with the development of a
2’-O-methyltransferase mutant dengue virus showed promising ﬁrst results164.
Together with IFIT5, IFIT1 was originally described as a PPP-RNA binding protein.
However, diﬀerences is some key residues are responsible that IFIT1 is able to bind
capped-RNA, whereas access to the cap-binding pocket is blocked in IFIT5. Replacement
of an arginine residue in IFIT1 to a threonine residue in IFIT5 causes several residues
to be pulled into the putative cap-binding pocket, which is then blocked. Interestingly,
nonplacental mammals seem to have an IFIT5-like protein that still carries the arginine
residue as IFIT1 does. These proteins therefore probably show a hybrid IFIT5/IFIT1
function and present a genealogical IFIT5/IFIT1 precursor protein. Together, the
work presented in this dissertation provides novel insights into important areas of
nucleic acid immunity. Restricting virus replication and spread is the most important
objective innate immunity is able to accomplish and represents an eﬃcient and powerful
mechanism to prevent detrimental outcomes for the organism.
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